HIV/AIDS AND HOMELESSNESS:
Recommendations for Clinical Practice
and Public Policy -
November 1999
This document
also available in PDF 264KB.
Index:
-
Executive Summary
-
Introduction
-
HIV
Prevention
-
Access to Care
-
General HIV Care
-
Antiretroviral Treatment
-
Adherence
-
Research
Go to
Table of Contents
HIV/AIDS & HOMELESSNESS
Recommendations for Clinical Practice and
Public Policy
Developed for The Bureau of Primary Health Care
and The HIV/AIDS Bureau Health Resources and Services Administration
by
John Song, M.D., M.P.H., M.A.T.
November 1999
i
Financial and other support for the development and distribution
of this paper were provided by the Bureau of Primary Health Care and the
HIV/AIDS Bureau, Health Resources Services Administration, United States
Department of Health and Human Services, to the National Health Care for the
Homeless Council, Inc., and its subsidiary, the Health Care for the Homeless
Clinicians' Network.
The views presented in this paper are those of the author and do
not necessarily represent those of the United States government or of the
National Health Care for the Homeless Council. Nothing in this paper should be
construed as providing authoritative guidelines for the practice of medicine or
for treatment of medical conditions.
This paper may be reproduced in whole or in part with appropriate
recognition to the author, John Y. Song, MD, and the publisher, the Health Care
for the Homeless Clinicians' Network, National Health Care for the Homeless
Council, Inc.
Second Printing
February, 2000
National Health Care for the Homeless Council
Health Care for the Homeless Clinicians' Network
Post Office Box 60427
Nashville TN 37206-0427
Phone 615/226-2292
Fax 615/226-1656
council@nhchc.org or
network@nhchc.org
http://www.nhchc.org
ii
PREFACE
HIV/AIDS and homelessness are twin plagues that take a staggering
toll. Each condition complicates
the other, and lives hang in the balance as health care providers
and their patients try to sort through
the complications and assure critical services. This paper is
dedicated to the improvement of
HIV/AIDS care for homeless people, and to the end of both of
these plagues.
In considering HIV/AIDS and homelessness together, this paper
explores largely uncharted territory.
Its principle author, Dr. John Y. Song, brought to the task his
insight from treating HIV-infected people
as a volunteer with Health Care for the Homeless, Inc., of
Maryland, and writing skills honed in
part through his experience as a leader of a homeless writers'
group in Baltimore. He also brought a
kind and generous heart. We are grateful that Dr. Song chose to
devote part of his dual fellowship in
General Internal Medicine and in Ethics and Public Policy to this
project. The Johns Hopkins School
of Medicine and Georgetown University deserve appreciation for
the support they provided for his
endeavor.
In defining the parameters of the paper, Dr. Song consulted with
an HIV/AIDS Advisory Committee
of the Health Care for the Homeless Clinicians' Network, whose
members also reviewed various
drafts as the work progressed. Advisory Committee members are
listed in Appendix IV. Brenda J.
Proffitt, MHA, ably staffed and guided the Committee in her role
as Project Director for the HCH
Clinicians' Network.
A Symposium on HIV/AIDS and Homelessness - convened by two
agencies of the Health Resources
Services Administration, the Bureau of Primary Health Care and
the HIV/AIDS Bureau -
brought together researchers, HIV-infected homeless people,
health care providers, HIV/AIDS specialists
and homeless advocates to contribute further advice to the
project. Many of the recommendations
in this paper emerged from that very productive Symposium.
Participants are listed in
Appendix V.
Special thanks is due to Jean L. Hochron, MPH, and Lori S. Marks,
BA, of the Bureau of Primary
Health Care's Division of Programs for Special Populations, for
understanding the need for this publication
and for guiding its development. Equally valuable were the
support and resources provided by
HRSA's HIV/AIDS Bureau staff, particularly Magda L. Barini-Garcia,
MD, MPH, and Kim Y. Evans,
MHS. Patricia A. Post, MPA, Communications Manager for the
National Health Care for the
Homeless Council, edited this paper into its final form with
remarkable skill. Carlos Velez also provided
editorial assistance.
Thank you to all who contributed to the work represented here,
and to the many others who struggle
against HIV/AIDS and homelessness each day.
John N. Lozier, MSSW
Executive Director
National Health Care for the Homeless Council
iii
TABLE OF
CONTENTS
I. EXECUTIVE SUMMARY
II. INTRODUCTION
III. HIV PREVENTION
A. Background
1. Substance Abuse Treatment
2. Mental Health Care
3. Targeted Prevention
4. Harm Reduction
B. Recommendations
1. Clinical Recommendations
2. Public Policy Recommendations
IV. ACCESS TO CARE
A. Background
1. Barriers to Health Care
2. HIV Counseling and Testing
3. Continuity of Care
4. Appropriate and Proficient Care
B. Recommendations
1. Clinical Recommendations
2. Public Policy Recommendations
V. GENERAL HIV CARE
A. Background
1. Immunizations and Testing
2. Tuberculosis
3. Homeless Women
4. Rural Areas
B. Recommendations
1. Clinical Recommendations
2. Public Policy Recommendations
iv
VI. ANTIRETROVIRAL TREATMENT
A. Background
1. Treatment Failure
2. Resistance
3. Combinations without Protease Inhibitors
4. Access
B. Recommendations
1. Clinical Recommendations
2. Public Policy Recommendations
VII. ADHERENCE
A. Background
1. Adherence Assessment
2. Reasons for Non-Adherence
3. Maximizing Adherence
4. Public Health Considerations
B. Recommendations
1. Clinical Recommendations
2. Public Policy Recommendations
VIII. RESEARCH
A. Background
1. Needs Assessment
2. Priorities
B. Recommendations
1. Epidemiology
2. Behavioral Research
3. Clinical Research
4. Policy Research
Appendix I - REFERENCES
Appendix II - CASE HISTORIES
Appendix III - GLOSSARY
Appendix IV - HCH CLINICIANS' NETWORK
HIV/AIDS ADVISORY COMMITTEE
Appendix V - SYMPOSIUM ON HIV/AIDS AND
HOMELESSNESS PARTICIPANTS
1
I. EXECUTIVE SUMMARY
This document is intended for clinicians and other service
providers, health care policy makers and
advocates. It was developed by the National Health Care for the
Homeless Council in collaboration
with the Bureaus of Primary Health Care and HIV/AIDS, Health
Resources and Services Administration,
Department of Health and Human Services, in response to the
following concerns:
-
The prevalence of HIV/AIDS is dramatically higher among
homeless people than in the general population.
-
Homelessness and HIV/AIDS are widespread and intersecting
problems that occur in both urban and rural populations throughout the United
States.
-
Conditions associated with homelessness make HIV prevention and
control especially difficult.
-
Limited access to medical care severely restricts HIV/AIDS
prevention, risk reduction and treatment for homeless persons.
-
Adherence to complex HIV treatment regimens presents special
challenges for homeless patients and their caregivers.
Of the 400,000 to 600,000 individuals currently estimated to be
living with AIDS in the United
States (CDC), approximately one-third to one-half are either
homeless or at imminent risk of
homelessness (Goldfinger, as cited in ACLU). Median prevalence
rates of the human immunodeficiency
virus (HIV) that causes AIDS have been found to be at least three
times higher -3.4% versus
under 1% - in homeless populations than in the general population
(Allen). Even higher
prevalence rates (8.5% - 62%) have been reported in various
homeless subpopulations, including
adults with severe mental illness (Zolopa; Paris; Susser;
Fournier; Torres).
Neither HIV nor homelessness is limited to urban populations.
Both problems are widespread, intersecting
in rural and urban areas across the United States. Although the
prevalence of HIV is likely
to be highest in large metropolitan areas, there is evidence that
the AIDS case rate is increasing
more in non-metropolitan areas (CDC). Among persons known to be
at highest risk for HIV infection,
including intravenous drug users and persons engaging in
high-risk sexual behaviors, those
without a stable home are even more likely to be HIV-positive,
wherever they may live (Wiebel;
Smereck).
Although new medications have reduced the number of HIV cases
that progress to full-blown
AIDS, antiretroviral therapy is not universally available.
Despite their disproportionately high risk
for HIV infection and transmission, homeless individuals have
limited access to preventive and
therapeutic HIV/AIDS care. Moreover, their limited access to
comprehensive health care delays the
identification of HIV, accelerates the onset of AIDS, and impedes
the resolution of behavioral disorders
that interfere with HIV risk reduction and treatment. Restricted
access to health care is also
a contributing factor in the increased prevalence of
opportunistic infections and other medical conditions,
including tuberculosis, that are more common among homeless
people than among other
groups.
2
To address these critical public health issues, access to health
care for homeless individuals must be
increased through expanded health coverage. Better coordination
of care must be achieved among
providers of clinical and social services, which must include
behavioral health care and housing. In
addition, continuity of care must be improved, especially
following admission to and discharge from
inpatient and criminal justice facilities.
HIV/AIDS Prevention
Preventive measures commonly used in other populations at
increased risk for HIV infection are
often unavailable to homeless men and women. Although homeless
shelters, food kitchens and
clinics are ideal settings for primary HIV prevention,
insufficient resources limit the health education
and risk reduction interventions these organizations can provide.
Nor are HIV testing and counseling generally available to
homeless individuals, who experience
unique barriers even when these services are available. Travel to
clinics for testing or to obtain test
results is often difficult for people experiencing homelessness,
and mobile testing is not provided
with sufficient frequency. Homeless persons testing positive for
HIV who seek care are often unable
to obtain referrals to HIV/AIDS specialty clinics. Compounding
these barriers is the lack of routine
screening of homeless individuals for sexually transmitted
disease, psychoactive substance abuse and
mental illness. Early identification and treatment of these
conditions would assist in HIV and AIDS
prevention.
A number of strategies shown to reduce HIV risks in the homeless
population, including substance
abuse treatment, needle exchange programs, safe injection
education and the provision of condoms,
are not routinely available. Linkages among primary care, HIV
treatment and behavioral health
services, though effective where they exist, are also limited.
Similarly, some clinical and social service
providers lack sufficient training to engage homeless clients'
active participation in HIV risk reduction.
To address these limitations, policy makers, community planning
groups and health care providers
must assure that HIV prevention programs are made available to
all homeless individuals, and that
preventive interventions are culturally, developmentally and
linguistically appropriate for the individuals
they are intended to influence. In addition, harm reduction
initiatives should be adequately
funded to reduce known risks of HIV infection for homeless
individuals. Finally, treatment for HIV,
substance abuse and mental illness should be linked to primary
care services and coordinated by experienced homeless providers.
Access to Comprehensive Health Care
Although many Americans have limited access to comprehensive and
well-coordinated health care,
individuals who experience homelessness are particularly
vulnerable to increased morbidity and
mortality when excluded from integrated medical and behavioral
health services. Among the most
significant health care access barriers are lack of health
insurance and financial resources, difficulty
managing entitlement processes, lack of transportation, and a
limited number of culturally and linguistically
competent caregivers who are willing and able to serve poor and
homeless people. Because
subsistence needs take most of their time and energy, most
homeless people relegate preventive
and primary health care to a lower priority in their lives. Lack
of provider flexibility (e.g., office
hours limited to times when homeless patients are unable to keep
appointments) makes needed care
even harder to obtain.
3
Influenza and other respiratory infections, diabetes, anemia and
liver disease are among the conditions
that tend to be more serious and complex for homeless
individuals, primarily because they do
not obtain care early. Lack of adequate food and financial
resources exacerbates medical problems.
All medical conditions are made more complex by HIV, which
disrupts the body's natural response
to disease. Thus it is essential for health care providers to
screen and treat homeless clients for a
wide variety of common medical conditions.
Access to HIV Care
While traditional homeless service providers and other
community-based clinics can provide necessary
primary care services, they often lack the resources and
expertise to provide sufficient HIV care.
Homeless individuals who receive health care services from safety
net providers may have limited
access to HIV testing and specialty care. Restricted access to
mental health and addictions treatment
can further delay and compromise the efficacy of HIV therapy.
Treatment should be made available for all conditions that impact
on HIV care, including other
sexually transmitted diseases, hepatitis, substance abuse and
mental illness. Goods and resources
that make care more effective, such as food, shelter and bathroom
facilities, should be provided
where necessary as an integral part of HIV care.
Prophylactic antibiotic therapy for opportunistic infections (OIs)
is relatively inexpensive and can
reduce morbidity and mortality in HIV-infected persons. Treatment
of these conditions can also
prepare homeless clients to adhere to more complex treatment
regimens. Nevertheless, not all
homeless people who need OI prophylaxis receive it. Whether
clinicians are not offering homeless
clients treatment, or whether they are refusing it (or both) is
unclear. In any case, clinicians should
be persistent and creative in their efforts to make OI
prophylaxis available to homeless clients, and
encourage adherence to antibiotic therapy.
Antiretroviral Therapy
During the last several years, biomedical research has produced a
variety of antiretroviral therapeutic
agents that have proven effective in suppressing HIV in infected
persons. Tests used to measure
HIV progression have also improved substantially with the
calculation of HIV viral loads in blood
plasma. The level of HIV in the blood can be seen as a predictor
of disease progression. Combinations
of various antiretroviral agents, when taken as prescribed, can
reduce viral loads to undetectable
levels in relatively short periods of time.
To be successful, antiretroviral therapy requires diligent
patient adherence to complicated treatment
regimens. Patients may have to take more than twenty pills in
several doses daily, following strict
dietary instructions. In addition, some individuals experience
severe side effects. Antiretroviral
therapy does not work for everyone, especially for individuals
who do not take their medications as
prescribed. They risk treatment failure and the development of
drug resistance. When a particular
treatment fails, the patient may not be able to resume it, as the
medication may no longer be effective
in suppressing the virus in that individual. In some instances,
failure of a particular medication
may mean that other medications are not effective either, due to
a phenomenon called crossresistance.
4
Prescribing antiretroviral therapy requires a detailed assessment
of the individual's health status and
lifestyle to assure that medications can be taken as prescribed,
with adjustments in therapy where
possible to maximize adherence. Especially promising for some
individuals are simpler proteasesparing
treatment regimens that achieve viral suppression while reducing
the risk of drug resistance.
An individual's viral load must be monitored closely in case it
does not respond to treatment or rebounds
after decreasing initially. If a patient fails a particular drug
combination, other combinations
may be prescribed.
Because antiretroviral therapy is expensive, it is not always
available to individuals who are poor and
homeless. Although antiretroviral medications are becoming more
affordable through government
programs and charitable sources, not all homeless individuals
have access to them or to clinicians
who are familiar with antiretroviral therapy. Additional steps
should be taken to make antiretroviral
therapy more accessible to homeless persons and to provide them
and their clinical providers with
the education and resources needed to make treatment successful.
Adherence
It is generally believed that failure of antiretroviral therapy
is most often due to lack of patient adherence
to the prescribed treatment regimen. Prior to prescribing
antiretroviral medications, physicians
determine whether a particular individual can or will adhere to
the therapy. Many homeless
persons are excluded from treatment because they lack stability,
housing, regular access to food,
water and other resources needed to ensure adherence to
antiretroviral therapy. In addition, substance
abuse disorders, which affect significant numbers of homeless
individuals, are generally considered
to be grounds for withholding antiretroviral therapy because they
can undermine patients'
capacity to adhere reliably to any treatment regimen.
Nevertheless, there are no absolute contraindications to
antiretroviral therapy. While it is important
to prescribe complex treatment regimens, where appropriate, to
individuals who can adhere to
them, it is also essential to assist others to obtain the most
effective alternative treatment available.
Clinicians and service providers should make an in-depth
assessment of the impediments their patients
may face in adhering to therapy. Rather than using the assessment
as a basis for denial of
treatment, physicians should respond to identified barriers by
working with their patients to overcome
them or prescribe regimens that are easier to follow. Where
possible, clinicians should prescribe
medications that can suppress HIV in simple combinations - a
rational strategy for all patients,
whether or not they have stable housing.
Patient adherence can also be facilitated through co-management
of care by clinicians, non-clinical
service providers and other individuals who are in regular
contact with homeless individuals. With
the exception of some case managers, non-clinical service
providers tend to be poorly informed
about antiretroviral therapy. It is essential, therefore, that
all homeless service providers obtain basic
information about antiretroviral therapy, including how it works
and how to manage side effects.
In this way, a variety of trained service providers and support
personnel can assist homeless patients
in maintaining appropriate adherence to HIV treatment.
5
Research
The research literature on HIV/AIDS and homelessness, though
sparse, clearly identifies barriers to
prevention, health care access and treatment faced by homeless
people living with HIV, and points
to a number of areas where more investigation is needed. More
targeted studies employing standardized
methodologies are needed to form a scientific basis for the
development of successful HIV/AIDS prevention and treatment strategies for
people who lack stable housing.
Such research is warranted by the preliminary evidence, reported
here, that HIV/AIDS has a disproportionate effect on particular homeless
subpopulations, and that HIV-infected, housed persons
are at increased risk of becoming homeless. Failure to measure
the scope of HIV/AIDS within the
homeless population and to develop effective prevention and
treatment strategies is likely to exacerbate
the serious public health problem which the human
immunodeficiency virus and its devastating
sequelae already present.
Epidemiological studies are needed to better characterize the
extent of HIV/AIDS among homeless
people and the extent of homelessness among persons with
HIV/AIDS. These include focused
studies on homeless subpopulations for whom HIV prevention and
care are known to be especially
problematic -e.g., rural populations, homeless women and
transgendered individuals. Behavioral
research is required to develop successful strategies for
decreasing HIV transmission among homeless
persons, and to identify individual characteristics that may
increase treatment adherence.
Clinical research is needed to measure the impact of
co-morbidities and nutritional deficiences on
HIV/AIDS progression, to quantify immunization rates and
determine outcomes of antiretroviral
therapy in the homeless population. Finally, policy research is
needed to document the impact of
health coverage on HIV-infected homeless persons' health and
access to care, and to develop strategies
to increase access to comprehensive health care for all homeless
people.
6
II. INTRODUCTION
L. T. started antiretroviral medications in 1997, taking them for
six months with diligence.
During that time, he was housed in a single residence hotel. When
he became
homeless again, however, he told me that he knew that he would
not be able to take
his medications as prescribed, and he did not want to take them
for fear of resistance.
For the last year, L. T. has been homeless and not taking
medication. His CD4 count
fell to 250 and his viral load climbed to over 300,000. He is
aware that he may be in
trouble medically.
- Barry Zevin, M.D., San Francisco
Between 1981 and 1999, the United States Public Health Service
reported 688,200 cases of acquired
immunodeficiency syndrome (AIDS). Currently, 400,000 - 600,000
U.S. residents are estimated
to be living with the human immunodeficiency virus (HIV) that
causes AIDS, and about
40,000 new cases of HIV are reported each year (CDC). An
estimated one-third to one-half of people
living with AIDS in the United States are either homeless or at
imminent risk of homelessness
(Goldfinger, as cited in ACLU).
A large, multi-site housing needs assessment survey found that
41% of respondents with HIV/AIDS
had been homeless sometime in their lives (Lieberman), and local
needs assessments from Los Angeles
and Philadelphia portray similar housing instability among those
with HIV/AIDS (Low;
Aquaviva). Given that homeless people in general are less likely
to be counted (Link) and are less
likely to be tested for HIV than housed individuals (Rockwell),
these figures probably underestimate
the scope of the problem.
The prevalence of HIV infection in homeless populations studied
is at least three times higher than
in the general population. A multi-site study tracking the spread
of HIV in 16 U.S. cities between
1989 and 1992 reported a median HIV seroprevalence of 3.4% among
homeless adults, compared to
less than 1% in the general population (Allen). Local studies
conducted during the 1990s in urban
areas with high HIV prevalence rates have reported even higher
rates of HIV infection in homeless
subgroups, ranging from 8.5% to 62% (Zolopa; Paris; Susser;
Fournier; Torres). Although the range
is broad because of different study protocols, locales,
subpopulations and definitions of homelessness,
these figures are significantly higher than the estimated
prevalence in the general population.
Among persons known to be at highest risk for HIV infection -
intravenous drug users and persons
engaging in high-risk sexual behaviors - those who do not have a
stable home are even more likely
to be HIV-positive (Wiebel; Smereck). A 1995 study found that 69%
of homeless adults surveyed
were at risk for HIV infection from unprotected sex with multiple
partners, injection drug use
(IDU), sex with IDU partners, or exchanging unprotected sex for
money or drugs (St. Lawrence;
ACLU). Homeless persons with severe mental illness and/or
chemical dependencies are especially
vulnerable to the disease because of their impaired capacity to
learn and practice risk reduction behaviors
(Susser).
Homeless people have alarmingly high HIV infection rates for a
variety of reasons, including engagement
in high-risk behaviors and the lack of resources to prevent HIV
transmission. For those
already infected, HIV antiretroviral therapy (ART) is often
delayed or never begun. Even when initiated,
treatment regimens are so complex that they pose adherence
difficulties that may result in
the development of drug-resistant strains of the virus. Lack of
health insurance, transportation,
7
housing and other subsistence needs make health care extremely
difficult for homeless individuals to
obtain, resulting in poorer health and diminished capacity to
resolve problems that led to their
homelessness in the first place. When these problems are
compounded by HIV/AIDS, they are beyond
the capacity of homeless individuals to solve alone.
In response to these issues, the National Health Care for the
Homeless Council initiated a project in
1998 to gather more detailed information about HIV and
homelessness in the United States. Intermediate
goals were to explore problems encountered by clinicians serving
homeless people who are
engaged in HIV prevention and treatment, and to derive from their
experience recommendations
for clinical practice and public policy. The ultimate goal of
this project is to improve HIV prevention
and care for all people who are homeless.
John Song, M.D., M.P.H., M.A.T., volunteered to spearhead this
effort while completing dual fellowships
in General Internal Medicine at The Johns Hopkins University
School of Medicine, Baltimore,
Maryland, and in Ethics and Public Policy at Georgetown
University, Washington, DC. Dr.
Song conducted a comprehensive literature review, interviewed HIV
specialists and other clinicians
experienced in treating homeless persons with HIV/AIDS, and
conducted a survey of homeless
service providers through the Health Care for the Homeless
Clinicians' Network. On March 19-20,
1999, the Bureaus of Primary Health Care and HIV/AIDS of the
Health Resources and Services
Administration hosted a symposium to discuss HIV/AIDS and
Homelessness, involving HIVinfected
homeless people, health care providers, researchers, advocates
and policy makers. Dr. Song
summarized these discussions and information gathered from other
sources to develop this document,
in collaboration with the National Health Care for the Homeless
Council.
The document is intended for clinicians and other service
providers, policy makers and advocates,
and contains information that should help all of these parties to
better understand and address a variety
of issues faced by persons living with HIV. The document explores
current practices of clinicians
who provide HIV care to homeless patients, including factors they
should take into account
when prescribing highly active antiretroviral therapy (HAART). It
also identifies deterrents to
HIV/AIDS prevention and optimal care for homeless individuals,
and suggests directions for further
discussions among clinicians and policy makers to help overcome
these barriers.
8
III. HIV PREVENTION
S. A. was 21 years old when I met her in March 1997. She was
brought to our urgent
care clinic by an outreach worker who told me that S. A. only
spoke Spanish and was
recently released from jail for prostitution. She was at the time
in one of the city shelters,
where our medical and social services staff had established a
satellite clinic. S.A. is
a transgender male to female, who tested HIV-positive a year
before. She was rejected
by her family in Mexico and came to the U. S. two years ago with
a boyfriend. Shortly
after arriving in the States, S. A. was alone and depending on
sex work for an income.
She had multiple sexual encounters without protection, at her
clients' requests. She
was smoking methamphetamines and using injectable estrogens as
frequently as she
could to keep her feminine characteristics.
- Linette Martinez, M.D., San Francisco
A. Background
Homeless individuals engage in behaviors that place them at high
risk for HIV infection, and do so
at alarming rates. These behaviors include injection drug use (Rekart;
Erickson; Lieberman), highrisk
sexual behavior (Johnson; Hudson; Kouzi), needle-sharing
(Williams; Rekart; Beardsley; Bluthenthal),
shooting gallery use (Celentano; Beardsley), and exchange of sex
for money or drugs
(Schilling; Corby). High-risk behaviors are motivated by the need
to subsist on the streets, by cooccurring
mental illness and substance abuse, and by a peer culture that
encourages these behaviors.
Data regarding the prevalence of addictive disorders among
homeless people are varied. Studies
conducted in the 1980s, from which high prevalence rates are
often quoted, over-represented longterm
shelter users and single males, among whom rates of substance
abuse are known to be especially
high. Moreover, these studies reported lifetime substance use
rather than current addiction
(NCH). It is estimated that the prevalence of drug use among
homeless people is 30-40% (Koegel),
although some studies have demonstrated even higher proportions (Susser;
Spinner; Robertson).
Substance Abuse Treatment
Although there are no generally accepted prevalence rates that
accurately describe the proportion of
all homeless adults engaging in substance abuse, addictions are
generally acknowledged to be more
prevalent in homeless than in domiciled populations.
Nevertheless, treatment for substance abuse
and dependence is not usually available to homeless men and
women, who are sometimes denied
treatment because they are homeless. Active substance abuse is
associated with lack of access to
HIV care and poor adherence to antiretroviral therapy (Samet;
Eldred; Ohmit).
In a study conducted by the HCH Clinicians' Network, 78% of
homeless health care providers surveyed
found it difficult to obtain substance abuse treatment for their
HIV/AIDS patients
(HCHCN). Other studies found that less than half of homeless
individuals in need of addiction
treatment obtained it (NCH), and that patients were excluded from
treatment because they were
homeless (Oakley). Although estimates of the prevalence of
alcohol and other drug use among
homeless individuals vary, alcohol use and alcohol use disorder
are acknowledged to be more common
among homeless than domiciled individuals (Robertson; Susser;
Breakey; Wright).
9
Mental Health Care
High-risk behaviors are practiced regardless of a co-occurring
mental illness (Valencia; Susser;
Goldfinger; Fischer), but mental illness is both an impetus and a
consequence of substance abuse in
many homeless people, and can exacerbate high-risk behavior.
Mental illness also complicates HIV
prevention and care (Ferrando; Singh; Chesney). Like addiction
treatment, mental health services
for homeless people are often inadequate (Oakley). The HCHCN
survey found that 69% of providers
had difficulty obtaining mental health services for their
homeless patients.
Targeted Prevention
Homeless men and women engage in the exchange of sex for money or
drugs, but lack the resources
to engage in safer sexual or other practices. Homeless women with
children may place themselves at
increased risk for HIV transmission in response to the economic
pressure of having to provide for
their families with few marketable skills. Individuals identified
as homeless are more likely to engage
in high-risk behavior during periods of homelessness compared to
periods of relative stability
(Celentano).
Few prevention programs are designed for people without stable
housing, and studies demonstrate
that existing risk reduction interventions may not be as
effective for homeless individuals as for their
domiciled counterparts (Clatts; Abdul-Quader). Nevertheless,
successful risk reduction has been
demonstrated in homeless populations as a result of targeted
prevention programs (Nyamathi;
Susser; Goulart).
Harm Reduction
Harm reduction refers to activities that are designed to reduce
or minimize the damage caused by
high-risk behaviors such as injection drug use and prostitution
(McMurray-Avila), with the ultimate
goal of eliminating these behaviors. Essential to the process of
harm reduction is engagement, with
the realization that elimination of high-risk behavior may take
time and small steps. Harm reduction
techniques include needle exchange programs, safe injection
education (such as sterilizing needles
with bleach), safer sex negotiation, and relapse policies which
recognize that treatment success
is often preceded by multiple episodes of failure.
B. Recommendations
Clinical Recommendations
HIV prevention and risk reduction should be an integral part of
any program serving homeless people.
To be successful, prevention initiatives should include the
following elements:
-
Provider training. All service providers who work with
homeless people on a regular basis, both clinical and non-clinical, should be
trained in HIV prevention.
-
Engagement. Primary care providers should inquire
tactfully but persistently about high-risk behaviors as a routine part of
clinical assessments. Clinicians should provide HIV prevention and risk
reduction information and resources to their homeless clients, and should
actively engage them in preventing risky behaviors.
-
Cultural sensitivity. Information about HIV prevention
and risk reduction should be culturally
10
and linguistically appropriate for the people expected to
benefit from it. More educational materials targeted to particular homeless
populations should be developed and made available.
-
Outreach. Street-based outreach is needed to convey HIV
prevention information and resources to unsheltered homeless persons. Targeted
outreach to special populations - women, transgendered individuals, persons
with chemical dependencies and rural populations - is particularly needed.
Prevention strategies should include providing access to condoms and clean
needles. Outreach services must be linked to HIV counseling and testing and to
primary care services.
-
Multidisciplinary linkages. Because many homeless people
have multiple and complex health conditions that heighten their risk for HIV
infection, risk reduction interventions should involve clinicians from
multiple disciplines. All programs serving homeless individuals should
establish linkages with and provide referrals for primary care, substance
abuse treatment and mental health services.
-
HIV screening and testing. Access to HIV screening and
provision of HIV prevention information in shelters and mobile units are
essential parts of risk reduction. Incentives should be provided to encourage
patients to return for test results. Testing and treatment for sexually
transmitted diseases should also be provided, when necessary.
-
Substance abuse treatment. Substance abuse treatment
providers should assess their clients' living conditions
prior to beginning and concluding treatment. Homeless individuals should be
given priority for in-patient addiction treatment and for referrals to support
services including transitional housing following discharge.
-
Harm reduction. Harm reduction should be an integral
component of HIV prevention. Health care and other service providers should be
trained in introducing and advocating harm reduction techniques. Substance
abuse treatment programs should adopt relapse policies that incorporate the
concept of harm reduction.
Public Policy Recommendations
Support is needed for the following targeted HIV prevention
activities:
-
Housing. Better linkages should be established among
housing programs, health departments, HIV prevention programs and health care
providers. Housing for homeless people should be funded as a preventive health
measure.
-
Community planning groups. State and local HIV
Prevention Community Planning Groups should place a high priority on the needs
of homeless persons.
-
Harm reduction. Interventions designed to reduce HIV
transmission risks for injection drug users, especially needle exchange
programs, should be adequately funded to provide clean needles, syringes and
substance abuse treatment.
-
Mental and behavioral health care. Funding should be
increased to provide more on-demand
-
substance abuse and mental health treatment.
11
IV. ACCESS TO CARE
Larry is a 52-year-old black man who was first seen in the
Homeless Health Care
Center on May 17, 1988. At the time, he was sleeping on the
street and in shelters.
During 1988, he had eight clinic visits, mainly to treat multiple
episodes of tracheobronchitis
and to monitor his blood pressure. On April 5, 1990, he left the
clinic
without being seen. During the next two years, Larry visited
intermittently. His use of
alcohol and crack was heavy during this time. On August 2, 1994,
he returned to the
clinic with a laceration under his right eye; he also informed
the staff that he had been
HIV-positive since May. Labs were ordered, but Larry left without
having his blood
drawn. He was referred to a caseworker, but he also left without
seeing the caseworker.
In September, he finally came back to have his blood drawn; his
CD4 count at the
time was 480. He was not seen until August 1997. He had been
receiving care at the
VA, and brought in his medications - AZT, Epivir, Phenergan, and
Desipramine.
The prescriptions were filled.
- Ardyce Ridolfo, MSN, FNP, RNC, Chattanooga, TN
A. Background
Barriers to Health Care
Homeless men and women face a host of barriers to health care,
including lack of awareness of
services and resources, suspicion of health care institutions,
lack of insurance, competing subsistence
needs, transportation difficulties, lack of comprehensive
services and poor provider attitudes
(McMurray-Avila; Gallagher; Gelberg; Woods; Brickner). As a
result, many homeless people have
no regular source of health care, and fail to seek or obtain
medical attention even for known medical
conditions. Moreover, despite having more serious and complex
health conditions than poor
people who are housed, homeless individuals have demonstrably
less access to health care.
-
A study of homeless individuals in Los Angeles found that 66%
had no medical insurance, 56% had no regular source of care, and study
participants had, on average, 2.9 physician contacts in a year. These figures
are contrasted to a national poverty sample of housed people which reports 36%
without insurance, 24% without a regular source of care, and 6.3 physician
contacts a year (Gallagher).
-
Another study from Los Angeles reported that 14% of homeless
respondents had never sought medical attention for a known medical condition
and only 51% with a known medical condition had sought medical attention in
the previous year (Roper). Only 47% of homeless men and 30% of homeless women
in Baltimore could name a usual source of care (Breakey). Access barriers are
exacerbated for homeless individuals living with HIV/AIDS, which is associated
with poorer health care access than other chronic conditions (Cunningham). The
HIV Costs and Services Utilization Survey (HCSUS) found that large proportions
of people living with HIV who needed medical care did not receive it because
of competing subsistence needs such as food, housing, or transportation
(Cunningham).
12
-
In one study, HIV-positive individuals who were homeless had
fewer ambulatory visits than those who had homes (Arno). In a New York City
shelter with a 62% HIV seroprevalence rate, only 10% of homeless clients
requested medical help (Torres). Similarly, the Boston Health Study found that
homeless people with AIDS had three times more difficulty accessing care than
did housed people with AIDS because of unmet needs (Weissman).
-
The Health Care for the Homeless Clinicians' Network (HCHCN)
found that primary care clinicians experience difficulty obtaining various
kinds of health care for large percentages of their homeless HIV/AIDS
patients: general non-HIV/AIDS care (58%), subspecialty care (73%), respite
care (57%) and case management (48%).
Several factors affect HIV-infected homeless persons' health and
access to health care:
-
Housing. An essential element of successful HIV/AIDS
care is housing, which provides a place to store medication and food, a stable
water supply, bathroom facilities, a secure place to rest, a dependable
contact location, protection from harm, emotional security and hope. The lack
of safe and stable housing has a significant negative impact on the health of
homeless people with HIV/AIDS (Lieberman; Low; Song). A study from Los Angeles
found that 50% of housed individuals with HIV/AIDS felt they were at high risk
of becoming homeless (Low). An evaluation in Philadelphia found 44% of persons
with HIV/AIDS living in residences they were unable to afford, a significant
risk factor for subsequent homelessness (Acquaviva).
-
Health insurance. Lack of health coverage is associated
with lower access to HIV/AIDS care (Cunningham; Hecht). The HIV Costs and
Services Utilization Survey revealed that only 15.6% of homeless individuals
with HIV/AIDS had any kind of medical insurance (Arno). This problem is
becoming more acute; homeless clinics nationally reported a 35% increase in
the number of clients who were uninsured between 1996 and 1997 (O'Connell).
-
Entitlements. Although homeless individuals with an AIDS
diagnosis may obtain Medicaid disability coverage, an HIV diagnosis alone does
not trigger either Medicaid eligibility or coverage of HIV care in many
states. This distinction between HIV and AIDS impedes early aggressive care,
which is essential for treatment success.
-
Transportation. Fragmentation of services is a
significant access barrier. Clients must often travel to several different
locations to obtain necessary care and services. Many clients do not have
financial resources to pay even minimal transportation costs.
-
Racial and ethnic background. Most studies on homeless
populations with HIV/AIDS have been conducted predominantly among
African-Americans (Zolopa; Fournier; Lebow; Allen) who have been shown to have
less access to HIV care than white Americans (Pfeffer; Solomon; Stone;
Easterbrook).
-
Confidentiality. HIV/AIDS remains a stigma. Because
HIV-infected homeless people are often shunned even by shelter staff and other
homeless people, they do not want others to know they are receiving HIV/AIDS
care (ACLU). Respecting confidentiality and advocating for patient rights
under the Americans with Disabilities Act, if necessary, are essential to an
ongoing clinical relationship with these clients.
-
Compassion. Clients often feel isolated and distrustful
of institutions. Providers and clinicians are not always compassionate in
their care and may not pay attention to the special needs of homeless
individuals. Empathy and compassion are necessary for successful engagement
and treatment, particularly when caring for a population that has been
traditionally marginalized.
-
Incarceration. Many criminal justice facilities provide
substandard or inadequate HIV care or
13
none at all. Because inmates cannot use outside care
facilities, they may be excluded from HIV
care altogether.
-
Special populations. Women, homeless people in
non-metropolitan statistical areas (MSAs), undocumented immigrants and
transgendered individuals experience even greater barriers in obtaining health
care than do other homeless people with HIV/AIDS. Family responsibilities
often prevent women without stable housing from seeking care for themselves.
Homeless people in small towns and rural areas have fewer available health
facilities, and must travel greater distances to obtain care. Undocumented
immigrants experience legal, health coverage and language barriers to health
care, and trangendered individuals are less likely to seek services because of
fear of discrimination and violence.
HIV Counseling and Testing
Homeless people do not have sufficient access to HIV testing. A
large study of injection drug users
in New York City found that only 45% of homeless participants had
ever been tested for HIV, compared
to 58% of housed participants (Rockwell). A shelter-based study
in New York City reporting
an HIV seroprevalence of 62% found that only 18% of participants
had ever received an HIV test
(Torres); and in San Francisco, investigators found that only 25%
of homeless individuals living
with HIV had ever been tested before the study began (Zolopa).
Rates of return to obtain HIV test
results are also poor, with a 66% return rate reported in Atlanta
(Paris) and 70% in New York City
(Torres). A study in New Haven, Connecticut, found that only 23%
of homeless people ever tested
knew their HIV status (Barry).
Eligibility for public assistance, such as Medicaid, is one
incentive for homeless individuals to ascertain
their HIV status. Another is learning that chances for successful
treatment increase with early
diagnosis. There are, however, legitimate reasons why some
patients refuse an HIV test or fail to
return for test results, despite the availability of new
treatments - including the debilitating psychological
burden of a positive diagnosis (O'Connell) and fear of
discrimination (Gostin; Harvey;
Torres).
Continuity of Care
Even if available, health care services may not be fully
accessible to homeless individuals, many of
whom lack the transportation necessary to travel to various sites
where care and services are available.
Care facilities may also lack some of the basic necessities that
many individuals take for
granted, such as public bathrooms, accessible food and water, and
linkages to housing. Finally,
clinic personnel may not be familiar with the needs of homeless
persons. Overworked doctors and
nurses in many public health facilities may not have sufficient
time to question homeless patients
about problems they may be having that affect their health care,
or to offer these patients the emotional
and logistical support they need. Moreover, some clinicians may
not be able to hire adequate
numbers of full-time support staff, depending instead on rotating
part-time or voluntary providers.
Not all persons who receive care are able to continue to obtain
needed services. Health care may be
discontinued when individuals lose or change health coverage,
when they are incarcerated or when
eligibility requirements for public assistance programs change.
Disruptions in HIV care can also be
caused by inadequate transportation, competing subsistence needs,
lack of institutional capacity,
admittance to and discharge from inpatient facilities and jails,
migration, loss of housing and
changes in employment.
14
Many homeless people receive primary care at facilities with
inadequate links to inpatient care. Providers
may be unaware of changes in patient health, housing or insurance
status. Unaware of
HIV/AIDS patients' housing instability or unresponsive to their
need for transitional housing, hospitals
may discharge individuals directly onto the street without
follow-up care. Unless health care
providers are able to address the many barriers that homeless
individuals face in obtaining and
maintaining health care, homeless men and women will not receive
the long-term care that is required
for HIV treatment.
People without stable housing have less success in keeping
referral appointments (Schlossstein),
have poor follow-up for HIV tests (Torres; Barry; Paris) and lack
usual sources of care (Gallagher;
Breakey). There is evidence, however, that health care can be
successfully provided to HIV-infected
homeless persons. The Boston Health Care for the Homeless Program
found that homeless people
with HIV were not presenting to a clinic at significantly later
stages of the disease than others, and
that those with a primary care provider made an average of 14.1
visits over a 17 month period (Lebow).
Other encouraging results from an observational study of care in
San Francisco revealed that
72% of homeless persons with HIV/AIDS could name their primary
care provider and 92% were still
enrolled after two years (Bangsberg).
Appropriate and proficient care
Patients experience better health outcomes when their health care
providers have extensive
HIV/AIDS expertise (Kitahata). Unfortunately, expert HIV care is
not generally available to patients
who are homeless. Homeless individuals may have access only to
clinicians and other service
providers who are not trained in HIV/AIDS care. Few non-clinical
service providers have accurate
knowledge about HIV/AIDS or the special needs of clients who are
undergoing treatment for the
disease (ACLU).
The effectiveness of care for homeless individuals with HIV is
also influenced by their health care
providers' level of proficiency in both HIV/AIDS care and
homeless care. Because a significant and
growing number of people are infected with HIV and are either
homeless or at risk of homelessness,
providers require dual proficiencies. Cross-training of providers
in both HIV/AIDS care and the care
of homeless people is necessary to meet the needs of the
expanding homeless and HIV-positive
population.
The appropriate training and specialization of providers who
practice primary HIV/AIDS care has
been a national concern. Even when homeless people have access to
specialty HIV clinics, they
continue to seek care at homeless primary care clinics because of
their familiarity and convenience.
Therefore, homeless providers will always need to be proficient
in the primary care of HIV-infected
individuals.
Homeless people with HIV/AIDS often work with service providers
other than clinicians. With the
exception of HIV/AIDS case managers, very few of these personnel
have sufficient knowledge of
HIV/AIDS care. Individuals who manage shelters and control access
to medications, food and water
often lack basic understanding of antiretroviral therapy,
including the timing of medications,
food and water requirements, and the need for strict adherence to
treatment regimen.
15
B. Recommendations
Clinical Recommendations
1. Initial assessment. Intake
interviews for homeless men and women should include a housing
assessment. During the initial visit, providers should assess the
health care access barriers each
patient may face, including:
-
Knowledge, attitudes and past experiences with health care and
health care providers;
-
Financial, employment, housing, and insurance status;
-
Subsistence needs (food, water, shelter, etc.);
-
Transportation requirements;
-
Need for treatment of mental illness and/or active substance
abuse; and
-
Caregiver status and family responsibilities.
Providers should be alert to additional access barriers faced by
homeless women, racial and ethnic
minorities, undocumented immigrants, migrant farm workers, rural
populations, parolees,
homosexuals and transgendered individuals, including fear of
violence and discrimination.
2. Individualized care plan. Clinicians
and case managers should develop individualized care plans
for their patients, addressing the special needs of homeless
persons identified during and after
the initial assessment. An example might be making arrangements
with local public transportation
authorities to accommodate patients unable to walk to clinic
appointments and seeking
funding for travel support, where needed.
3. On-site services. All services
required by HIV/AIDS patients should optimally be available at
the same location.
4. Provider education. To serve the
growing population of HIV-infected homeless people, clinicians
must develop dual proficiencies in HIV/AIDS care and homeless
care. All service providers
who work with homeless individuals should be educated about basic
HIV/AIDS care principles
and practice. These workers include:
-
Physicians, nurses and other medical providers;
-
Mental health and substance abuse counselors;
-
Case workers and managers;
-
Peer counselors and outreach workers; and
-
Shelter and soup kitchen personnel.
Similarly, HIV specialists should be educated about the special
access barriers, co-occurring disorders
and non-medical needs of homeless clients.
5. Continuity of care. Better discharge
planning from hospitals and criminal justice facilities is
badly needed to promote continuity of care for homeless HIV/AIDS
patients. Properly designed,
centralized data systems may help to make this possible.
Providers should anticipate and attempt
to minimize potential disruptions in patient care caused by:
-
Changes in insurance benefit or eligibility status, including
loss of Medicaid;
-
Instability and loss of housing;
-
Fluctuations in subsistence needs and access to transportation;
-
Admittance to and discharge from inpatient facilities;
-
Incarceration and release from criminal justice facilities;
-
Seasonal changes;
16
6. Interdisciplinary and interagency linkages.
Health care providers should establish linkages to
non-clinical service providers to prevent disruptions in care.
Primary care providers and
HIV/AIDS specialists should develop collaborative relationships
to ensure quality of care, including
basic HIV/AIDS care and practice.
7. Provider flexibility. HIV/AIDS
caregivers should establish flexible hours to accommodate
homeless persons and to facilitate care for shelter dwellers who
may have curfews.
8. Patient confidentiality. In all
health care and service delivery settings, patient confidentiality
should be a priority; patients should be reassured that their
privacy is being protected by individuals
and institutions.
9. Compassionate care. Providers should
empathize with their patients through becoming better
informed about the difficulties they face, and should take steps
to remove health care access barriers
and to prevent and address homelessness.
10. Homelessness prevention. Linkages
to housing assistance programs such as Housing Opportunities
for People with AIDS and eviction prevention education should be
an integral part of
HIV/AIDS programs. In addition, better discharge planning from
hospitals and criminal justice
facilities is necessary to prevent homelessness from occurring.
Public Policy Recommendations
1. Outreach and HIV testing. More
public and private funding is needed for HIV outreach and
testing programs for homeless people.
2. Health coverage. Medicaid coverage
should be expanded to include anyone infected with HIV
disease, regardless of the existence of clinical manifestations.
Ryan White CARE Act (RWCA)
funding and third-party payers should provide reimbursement for
necessary goods and services,
including some not routinely covered (e.g., substance abuse
treatment). The AIDS Drug Assistance
Program (ADAP, part of RWCA) coverage should continue during
incarceration, migration
or transience.
3. SAMHSA block grants. States that
receive substance abuse and mental health block grant resources
should demonstrate that they allocate money to the care of
homeless people living with
HIV/AIDS.
4. Coordination of public housing services.
Greater coordination is needed among government
agencies providing housing and HIV/AIDS services, including the
Department of Housing and
Urban Development and the Department of Health and Human
Services' Health Resources and
Services Administration.
5. Local health departments. Because
shelters, drop-in facilities and food lines are ideal sites for
health interventions, local health departments should help to
fund, maintain and increase their
involvement in these services. Local health departments should
employ individuals with expertise
in homeless health care and increase their support of homeless
service providers.
17
6. Interagency Council on the Homeless.
The Interagency Council on the Homeless should direct
more attention to problems associated with HIV/AIDS and enhance
necessary linkages
among other agencies.
7. Criminal justice. Jails and prisons
should ensure that HIV/AIDS care continues uninterrupted
during incarceration, and that appropriate discharge planning is
completed for former prisoners
with unstable housing arrangements.
8. Support for provider training. The
educational activities of the Bureau of Primary Health Care
and the HIV/AIDS Bureau should be expanded to include more
HIV/AIDS and homelessness
training for health center providers and staff as well as other
service providers.
18
V. GENERAL HIV CARE
I met Mr. R. in the homeless shelter around 1994. He had been a
resident of multiple
homeless shelters in the city as well as up and down the state of
California for the past
four years. A non-smoker and non-drinker, Mr. R was generally in
good health until
August 1990. At that time, he was residing in the Episcopal
Sanctuary Shelter, where
he was treated for a fever and cough for six weeks before being
admitted to San Francisco
General Hospital. I was doing outreach at the shelter, and found
him in his bed
with a fever of 103°F. I took him to the emergency room and
stayed with him until he
was admitted. Mr. R. was hospitalized for two days. He had an
unremarkable work-up.
However, his HIV test returned positive. Previously, he had
mentioned that he had
had a negative HIV test, but it turned out that he had end-stage
AIDS. Perhaps he
was in denial. His initial CD4 count was 8, and his viral load
was 300,000. His fever
turned out to be secondary to cryptoccocal meningitis and
pneumonia.
- Chuck Marion, M.D., San Francisco
D. W. is a 30-year-old female I first met in our urgent care
clinic in August 1997. She
insisted that she wanted to start antiretroviral treatment. At
that time, she was housed
via the AIDS Foundation and accompanied to the clinic by her
HIV-negative boyfriend
T. R., who seemed very supportive. She admitted to crack use, but
said that
both she and T. R. had been clean and sober for two weeks. On
July 22, her viral load
had been greater than 800,000 and her CD4 count was 187. On this
first visit, I did
something I probably would not do now: I wrote a prescription for
Zerit, Epivir and Viracept.
We discussed the necessity of adherence and possible side
effects. For some reason,
I sensed that D. W. was committed to sticking with therapy. .As
of October 29,
her viral load was undetectable and her CD4 count 446. During
much of 1998, D.W.
received care at BAPAC, the Bay Area clinic for HIV-positive
prenatal care. In June
1998, D. W. delivered a healthy HIV-negative baby girl; D. W. and
the baby received
peripartum AZT.I did not see D. W. again until September 14, when
she came to urgent
care with pharyngitis. She was using crack cocaine again. As of
September 30, she
was off ART with a CD4 count of 350 and an HIV viral load of
40,000.
- Alisa Oberschelp, M.D., San Francisco
A. Background
The treatment of homeless individuals with HIV/AIDS must include
vigilant control of associated
medical conditions that may complicate HIV care and cause health
to deteriorate. Homeless people
with HIV/AIDS are particularly susceptible to a number of other
medical conditions which, untreated,
may exacerbate their illness and even threaten their survival.
Crowded, unsanitary living
conditions increase their risk of exposure to communicable
diseases and parasites. Limited resources
result in unmet subsistence needs, reducing their natural
resistance to disease. Their vulnerability is
compounded by the gradual destruction of their immune system by
HIV. Limited access to routine
health care, described in the previous section, may increase the
severity of medical conditions
through delayed treatment.
Respiratory infections (Weinreb; Brickner) and infestations are
especially common (Brickner;
Wright; Gillis). One study found that 14% of homeless adults had
suffered from influenza the previous
year (Marwick). The prevalence of tuberculosis is higher among
homeless people than in the
19
general population (Brickner), and higher still in homeless
people whose immune systems are compromised
by HIV/AIDS (Zolopa; Torres; Saez; Gollub; Gordin). Infestations
such as scabies and
fleabites tend to be much more florid in people with HIV/AIDS,
and some conventional treatments
are ineffective in those with advanced disease (Berger).
Other prevalent conditions in the homeless population include
diabetes (White), hypercholesteremia
(Gelberg), anemia (Breakey) and chronic gastrointestinal tract
illnesses (Weinreb; Wright).
Homeless persons also have high rates of liver disease, most
often secondary to viral infection or alcoholism
(Wright). Neurologic disorders are also more frequent; one study
revealed that homeless
people were six times more likely than housed persons to suffer
from neurologic conditions
(Wright). Less well documented medical conditions include soft
tissue infections and peripheral
neuropathies.
Poor caloric intake, malnutrition (Gelberg; Weinreb; Wright;
Wiecha) and consequent loss of muscle
mass, common among homeless people, are associated with increased
AIDS morbidity and mortality
(Schambelen). As little as 5% loss of muscle mass over four
months is associated with an increased
risk of opportunistic infections and death (Wheeler).
The following studies document conditions that are more common
among homeless persons living
with HIV/AIDS:
-
A study from San Francisco reported 8.5 times greater
likelihood of infection with Bartonella quintana,
the bacterium that causes bacillary angiomatosis-peliosis (Koehler).
-
Researchers in Boston found differences in AIDS-defining
diagnoses, including esophageal candidiasis (17% vs. 9%) and disseminated TB
(9% vs. 2%) (Lebow).
-
A study from New York found higher rates of bacterial pneumonia
in HIV-infected persons (Torres).
-
A study in New York City reported 21% of HIV/AIDS patients with
syphilis and 43% having antibodies to hepatitis B (Torres).
-
A study from Baltimore not limited to HIV/AIDS found hepatitis
B seroprevalence to be 45% among homeless people (Osher); another revealed
that 37% of homeless injection drug users were hepatitis C (HCV)-seropositive
(Garfein).
In addition to other concerns about substance abuse, medication
interactions and painful HIVrelated
neuropathies may require the prescription of narcotics to
HIV-infected individuals with a
history of substance abuse. Homeless persons may sell these
prescribed medications on the street,
where there is an active market for over-the-counter and
prescription drugs.
Immunizations and Testing
Immunizations are critical for persons living with HIV/AIDS,
whose immune systems lose the capacity
to fight disease. Vaccinations for influenza, pneumococcal
infection and hepatitis A are absolutely
essential because of frequent outbreaks of these conditions among
shelter dwellers and high
rates of hepatitis C in the homeless population. Homeless people
have not demonstrated poorer
rates of completing hepatitis B vaccination regimens and should
receive this precautionary measure.
Co-infection with hepatitis C - which occurs in approximately 40%
of all HIV-positive individuals
- can hasten full-blown AIDS and death. Although no vaccine is
currently available to prevent
hepatitis C, HCV testing and antiviral therapy are recommended by
some clinicians, in addition to
hepatitis A and B immunizations, to reduce morbidity and
mortality in persons co-infected with
20
HIV (Dietrich).
In a Boston study, only 56% of homeless patients with HIV/AIDS
had received a pneumococcal or
influenza vaccination and only 36% had received testing for
syphilis; 46% had received PPD testing
for tuberculosis; 28% had received PAP smears; and 37% had been
tested for hepatitis B or C (Lebow).
A study from San Francisco revealed that 25% of homeless persons
with HIV/AIDS found to
be PPD positive had never been tested before (Zolopa). Less than
20% of a high-risk subset of
homeless people in New Haven had received a pneumococcal
vaccination, and only 27% had received
an influenza vaccination (Barry).
Tuberculosis
As mentioned, the prevalence of TB is higher among homeless
people than in the general population.
Crowding and poor ventilation, common in many homeless
facilities, make transmission easier;
poor access to health care prevents treatment of primary TB; and
suppression of the immune
function by HIV infection and other conditions common to homeless
people makes activation of TB
more likely (NHCHC). Latent TB prevalence is extremely high among
homeless persons with
HIV/AIDS, ranging from 32% to 67% in populations studied (Zolopa;
Torres). A study in New
York City found 22% of HIV-infected participants with active TB
and 4% with extrapulmonary TB
(Torres). Another study of homeless men with HIV/AIDS found a 50%
prevalence of active TB
(Saez). These figures are much higher than the 4.7% - 10%
prevalence of active TB generally
found among persons with HIV/AIDS (Gollub; Gordin).
Homeless people have poor rates of return to have tuberculin skin
tests read (Torres; Barry) and
poor rates of adherence (11% - 55%) to TB prophylaxis (Brudney;
Pablos-Mendez; CDC). Directly
observed therapy programs have also demonstrated poor adherence
to TB treatment regimens
(Nazar-Stewart; Burman), which is associated with high rates (19%
- 60%) of drug-resistant tuberculosis
(Pablos-Mendez; Morris; Barry). Nevertheless, successful
experiences with TB prophylaxis
and treatment are also reported, by programs that vary
dramatically in their approaches to adherence
promotion. Some interventions emphasize cultural sensitivity,
using peer advisors and financial
incentives (Pilote); others employ more coercive techniques such
as detention (Oscherwitz).
Homeless Women
As noted in the previous section, homeless women face special
barriers to health care. Like housed
mothers, homeless mothers tend to subordinate their own health
needs to those of their children;
but the extraordinary demands of raising a family without stable
housing are especially disruptive to
regular health care for these women. Stretched thin by multiple
roles as childbearer, caregiver and
provider, homeless mothers are often dealing simultaneously with
the psychological effects of trauma
and abuse (Bassuk). Competing subsistence needs and caregiver
roles have been found to adversely
influence health care access for women living with HIV/AIDS
(Shelton, Cunningham).
Moreover, the needs of women with children may be overshadowed by
those of single men, who
comprise the vast majority of clients served in many homeless
health care projects. Nevertheless,
women with families now constitute more than a third of the
homeless population (Weinreb). Although
having a family may increase or decrease accessibility to a
shelter, depending on the program,
having children usually hinders access to health care for
homeless mothers.
Single homeless women are more likely to have addiction
disorders, suffer from mental illness, and
21
trade sex for commodities or housing. They are consequently at
increased risk for contracting
HIV/AIDS, but may have difficulty obtaining addictions treatment,
mental health services and
screening for STDs, which could lower their risk.
Certain conditions that are more prevalent among homeless than
domiciled women have been
shown to be directly related to homelessness. Researchers in
Worcester, Massachusetts, found that
41% of homeless women had a history of substance abuse or
dependence compared to 34.7% of
housed women. Homeless women were less likely to have a regular
provider or source of care, and
were more likely to list lack of childcare as a barrier to care (Weinreb).
These findings were reproduced
in Los Angeles (Wood) and Philadelphia (Parker). A study in St.
Louis showed that 48.6% of
homeless women had a psychiatric disorder, compared with 31.7% of
low-income domiciled women
(Smith). Major depression was over twice as prevalent among
homeless women surveyed, and the
prevalence rate of posttraumatic stress disorder was more than
ten times higher for homeless than
housed women (Smith).
Homeless women are more likely to be victims of domestic violence
or sexual abuse than are housed
women (Weinreb; Wood). "Homeless women frequently associate with
men for protection and end
up being sexually abused; they are four times more likely than
domiciled women to be raped"
(Fisher, as cited in ACLU). Women with HIV/AIDS may suffer from
greater psychological stressors,
including violence. The National Institutes of Health Women's HIV
Interagency Study found that
nearly 50% of women with HIV had suffered sexual abuse in the
past, and 60% had experienced
domestic violence (Anderson).
Women with HIV are particularly susceptible to a number of
conditions including the human papilloma
virus, the most common genital tract infection, which is
associated with increased rates of
neoplasia (cervical cancer) and decreased immune function.
Because women have often been excluded
from clinical trials due to concerns about pregnancy (Mangino),
the effect of HIV medications
on pregnant women is not well understood. Preventing vertical
transmission of HIV from infected
mothers to their babies through pregnancy or breast-feeding is an
additional concern for these
women and their caregivers.
Access to care is related to the quality of care that women
receive. Less than half of homeless
women surveyed in a multi-site study from Massachusetts could
name "a family doctor or hospital
from which they had received 'helpful' treatment within the
previous year" (Bassuk). Investigators
in Philadelphia reported that 19% of homeless mothers could not
even identify a place where they
could go for care (Parker). HIV counseling, testing and treatment
are among the services which
women have particular difficulty obtaining. A multi-site study
found that significantly fewer women
than men received pre- and post-test HIV counseling (Weissman),
and women have been found to
have lower CD4 counts and higher HIV viral loads when they enter
care (Bartlett). Women are less
likely to be seen by an experienced clinician (Kitahata), and
less likely to receive OI prophylaxis or
antiretroviral therapy than men (Bartlett; Odem).
Rural Areas1
Measuring homelessness is difficult in rural areas, where there
are few shelters or places homeless
people congregate (NRHA), and where "doubling up" with friends or
family members is more common
than on-the-street homelessness. Nevertheless, rural homelessness
is a significant and growing
1 Adapted from comments by Martha McKinney,
Ph.D., President, Community Health Solutions, Inc.
22
problem. Extrapolations from statewide studies in Iowa and
Pennsylvania indicate that approximately
11% - 14% of homeless people in America live in rural settings
(Foster); two other statewide
studies estimate a proportion of 18% (NRHA).
The U.S. Public Health Service measures AIDS case rates according
to prevalence in metropolitan
statistical areas (MSAs) or non-MSAs.2 As of
December 1997, non-MSA residents accounted for
5.7% of cumulative AIDS cases and 7.2% of new AIDS cases reported
in that year (CDC). The
AIDS case rate increased by 60% in non-MSAs between 1991 and 1997
as compared to 43% in
large metropolitan areas (CDC).
Homelessness may not be as prevalent among individuals with
HIV/AIDS who live in rural areas as
among urban dwellers (McKinney), but studying HIV in rural
communities presents additional
challenges. Two studies of HIV patient migration patterns found
individuals leaving large cities to
live with their families in rural areas (Cohn; Davis). A third
study found rural HIV-infected women
living with family members, husbands, partners or friends
(McKinney).
Although homelessness manifests itself differently in rural and
urban areas, homeless individuals in
both settings have one thing in common - unstable and often
inadequate living arrangments.3 Evidence
that many individuals in rural areas live in inadequate housing
(McKinney) is substantiated
by the fact that more than half of substandard housing in the
United States is located there (Sowell).
Even though literal homelessness may be less frequent in rural
areas, individuals living there
with HIV/AIDS, like their urban counterparts, often lack running
water or refrigeration - conditions
that complicate HIV care (Berry; Sowell).
Persons who live in rural areas without stable and adequate
housing face some of the same health
care access barriers encountered by homeless persons in urban
areas. These barriers are exacerbated
by scarcity of concentrated resources, greater distances to
travel, rugged terrain or severe weather to
overcome in seeking health services, and fewer public modes of
transportation (McKinney; Berry).
In rural areas of the Southeast, people with HIV/AIDS often
travel as long as two hours to see an
infectious disease specialist in a tertiary care center
(McKinney).
Provider attitudes can negatively affect care for rural HIV/AIDS
patients, who tend to be diagnosed
2 The Office of Management and Budget defines a
non-metropolitan area (non-MSA) as either a county with a city of less than
50,000 residents or an area that is not part of a county or group of counties
with at least 100,000 people.
3 A homeless individual is defined in section
330(h)(4)(A) of the McKinney Act as "an individual who lacks housing (without
regard to whether the individual is a member of a family), including an
individual whose primary residence during the night is a supervised public or
private facility (e.g., shelter) that provides temporary living accommodations,
and an individual who is a resident in transitional housing." The Bureau of
Primary Health Care has expanded this definition in its description of Health
Care for the Homeless program expectations for federal HCH grantees to capture
the many faces of homelessness: "A homeless person is an individual without
permanent housing who many live on the streets; stay in a shelter, mission,
single room occupancy facility, abandoned building or vehicle; or in any other
unstable or non-permanent situation. An individual may be considered to be
homeless if that person is 'doubled up,' a term that
refers to a situation where individuals are unable to maintain
their housing situation and are forced to stay with a series of friends and/or
extended family members. In addition, previously homeless individuals who are to
be released from a prison or a hospital may be considered homeless if they do
not have a stable housing situation to which they can return. A recognition of
the instability of an individual's living arrangement is critical to the
definition of homelessness." (Principles of Practice for Health Care for the
Homeless grantees, Bureau of Primary Health Care/HRSA/DHHS, March 1, 1999)
23
later because HIV/AIDS is perceived to be an urban disease and
their physicians do not consider
them to be at risk (NRHA; McKinney). The HIV Costs and Services
Utilization Survey found that
only 1.4% of rural people living with HIV/AIDS were receiving
medical care in the area where they
lived (Cohn, 1994). Even if physicians are available, many rural
providers do not have adequate
HIV experience (McKinney).
Confidentiality may be more difficult to preserve in rural areas
(McKinney). Rural residents with
HIV/AIDS are less likely to have medical insurance (Weslowski). A
comparison of urban and rural
responses to AIDS-related questions on the 1991 National Health
Interview Study revealed that
urban residents were 1.5 times more likely to have been tested
for HIV and 1.4 times more likely to
expect to have an HIV test than people in rural areas (Mainous).
Undocumented resident status
and transience, in addition to cultural and linguistic barriers,
make general HIV care more difficult
to obtain for migrant farm workers, who have extremely high rates
of tuberculosis and infestations.
Even when they are able to obtain care, persons living with HIV
in rural communities may not have
access to all of the diagnostic tools and routine treatments that
are presupposed by current standards
of care. A study of individuals receiving care in rural areas
during the first half of 1996 showed that
only 21% had ever had their HIV viral loads checked (Cohn). The
same study found that 63% of
homeless individuals with AIDS were receiving Pneumocystis
carinii pneumonia (PCP) prophylaxis,
and only 46% were receiving Mycobacterium avium complex
(MAC) prophylaxis (Cohn). Fewer
pharmacies carry front-line medications in rural communities,
especially where the demand is extremely
low (McKinney).
B. Recommendations
Clinical Recommendations
1. Standards of care. Service providers
should abide by evidence-based standards of care for
HIV/AIDS patients; a lower standard should not be used for people
who are homeless.
2. Medical history. HIV/AIDS providers
should be particularly thorough in documenting their patients'
medical histories, including results of the following
examinations and reports:
-
Oropharynx, focusing on poor dentition, candidal infections,
and nutritional deficiencies;
-
Skin and nails, looking for infestations, soft tissue
infections, bacillary angiomatosis-peliosis, trauma, liver disease, and
syphilis;
-
Neurologic, to assess for neuropathies, nutritional
deficiencies, syphilis, dementia, and mental illness;
-
Substance abuse, mental illness and medication histories; and
-
Frequent TB testing, up to once every six months.
3. Shorter prophylaxis. Providers
should take advantage of shorter prophylactic regimens and use
interventions that increase adherence to prophylatic TB therapy.
4. Immunizations. Health care providers
should administer recommended vaccinations, including
hepatitis B, as soon as possible.
24
5. Pharmacist education. Providers
should educate local pharmacists about the needs of homeless
persons living with HIV/AIDS.
6. Homeless women. Service providers
should address the barriers that homeless mothers face,
including lack of childcare, support services for their families
and help in obtaining public assistance.
Additional training is necessary to alert homeless service
providers to the importance of
providing linkages and referrals to HIV care for homeless women
and their families. The special
profile and risk factors of homeless women that should be
addressed include:
-
Caregiver status and motherhood,
-
Mental illness,
-
Domestic or other violence,
-
Substance abuse, and
-
High-risk sexual behavior.
7. Rural concerns. Service providers in
rural areas should address patient concerns about confidentiality,
transportation, and lack of providers and pharmacies. Health care
providers should
assess the dwellings of rural patients to determine adequacy of
shelter, medication storage capacity
and water supply.
Public Policy Recommendations
To improve general HIV care for homeless persons, more resources
should be devoted to the following:
-
Primary care. Increased access to primary care
providers, particularly in rural areas;
-
Nutrition and water. Improved availability of proper
nutrition and clean water;
-
Dental care. More accessible oral health care;
-
Immunizations. Vaccinations for hepatitis A and B,
influenza and pneumococcal infections; and
-
Women's health care. Mental health services, addiction
treatment, HIV testing and counseling.
25
VI. ANTIRETROVIRAL TREATMENT
Samuel is a 32-year-old man who entered our therapeutic community
for alcohol abuse
treatment. He had tested positive for HIV two years previously.
His blood work was
remarkable for a CD4 count of 410 and a viral load of 130,000. An
antiretroviral regimen
of AZT, Epivir, and Viracept was prescribed. It was stressed that
Viracept had to
be taken on a full stomach. We saw Samuel two weeks later
and-among other
things-reminded him to take Viracept after a full meal. He told
us he was doing so,
with the exception of Saturday and Sunday mornings. The shelter
in which the therapeutic
community was located served three meals on weekdays, but on
weekends
served only two meals a day - brunch (at noon) and dinner (in the
evening). So on
Saturdays and Sundays, Samuel took his morning Viracept on an
empty stomach.
- Elizabeth Lutas, M.D., New York City
Being housed and in a more stable situation - and seeing social
and nursing staff on a
regular basis - S. A. successfully recovered from rectal surgery
and kept her regular
follow-up appointments with me. In October 1997, almost six
months after her initial
visit and frequent subsequent visits, I felt comfortable and
eager to begin ART. She
started AZT, 3TC, and Nelfinavir. The regimen caused her only
minimal diarrhea, and
after a month her viral load had decreased considerably to 16,000
and her CD4 had
doubled. These results were encouraging, but after three months,
her viral load was
again over 300,000. S. A. disclosed to me that she had stopped
the Nelfinavir after the
first month because there were too many pills, and that very
rarely would she take the
3TC or AZT. A few months later, her CD4 count was 10, but we felt
ready to attempt
therapy again. With the assistance of the Bridge Project
physician and other staff, we
amplified and reinforced the message of adherence. Since May
1998, her viral load has
been undetectable, and her last CD4 count was 240. I keep
frequent visits with her.
.There are still many obstacles, however. Bridge Project housing,
for example, is
limited to 18 months.
- Linette Martinez, M.D., San Francisco
A. Background
In recent years, biomedical research has made significant strides
in the development of antiretroviral
agents that can delay the onset of AIDS. Antiretroviral therapy
(ART) is directed toward suppressing
the replication of HIV-1 (the most common HIV viral strain) in
order to improve HIVrelated
symptomology, preserve and restore immune function, and decrease
viral burden. There are
currently 14 approved antiretroviral drugs divided into three
classes that are prescribed in recommended
three-to-five drug combination cocktails called highly active
antiretroviral therapy
(HAART).
HAART has been demonstrated to profoundly suppress viral
replication, increase immune function,
and improve quality of life. It can also decrease the incidence
of opportunistic infections and other
AIDS-related conditions by as much as 75% - 80% (Pallela; Moore;
Hammer). Some anecdotal reports
indicate that HAART has led to long-term remission of CMV
retinitis and disseminated MAC
infections (Whitcup; McArthur). It may also lead to the
resolution of crytosporidiosis, microsporidiosis
and progressive multifocal leukoencephalopathy - conditions
previously thought to be incurable
(Carr; Hoffman). HAART is also associated with a significant
decrease in hospitalizations
26
for AIDS-related conditions (Torres; Goetz), a significant
decrease in mortality (Palella; Hogg;
Chaisson), and an incremental decrease in morbidity and mortality
(Palella).
HAART requires great diligence, attention and tolerance on the
part of the patient, as some regimens
may exceed 20 pills per day and may require two to three doses
daily. Timing and dietary requirements,
which must be observed to the letter, are critical to ensure
absorption and steady blood
levels.
Other concerns about the impact of ART include severe side
effects, need for hydration, refrigeration
and storage. The side effects can range from mild to life
threatening, and may cause many interactions,
requiring monitoring and evaluation of HIV viral load and CD4
count every three to four
months. These factors may decrease quality of life for patients
(Carpenter) and may prompt them to
discontinue therapy.
Treatment Failure
Drug treatment failure is defined as the confirmed detection of
plasma HIV virus after initial suppression
to undetectable levels, a persistent decrease in CD4 count, or
clinical deterioration and the
emergence of symptoms. Failure can be caused by primary or
cross-viral resistance, development of
secondary viral resistance, poor absorption of medications,
altered metabolism, multi-drug pharmacokinetics, and nonadherence (Carpenter).
The latter is considered the main reason for drug failure
and subsequent viral resistance (Sande).
Resistance
Resistance to individual antiretroviral agents is a major
concern, as already limited treatment options
may be reduced even more if the patient fails treatment.
Resistance can be caused by the selection
and transmission of resistant variants; by poor absorption,
altered metabolism, poor potency
and protein binding of antiretroviral medications; or by altered
host immune function (Mellors).
Once the virus has become resistant to a particular
antiretroviral drug, it may not sustain viral suppression
(Katzenstein).
Cross-resistance - the resistance to more than one antiretroviral
medications - means that once a
patient fails on a particular agent, the efficacy of others may
also be limited in the future (Gallant).
This is the case among the three approved drugs of the
non-nucleoside reverse transcriptase inhibitors
(NNRTI) class and, to a certain degree, protease inhibitors
(Gallant). Cross-resistance can also
impact the effectiveness of drugs in different classes. One study
demonstrated that nonadherence to
Didanosine, used in a triple-combination with Zidovudine (AZT)
and Nevirapine, resulted in resistance
to both Zidovudine and Nevirapine (Montaner).
Combinations without Protease Inhibitors
Due to concerns about resistance, practitioners and patients may
occasionally opt to emphasize delay
in the use of protease inhibitors while still seeking viral
suppression. Forty-eight week data from
a trial comparing the combination of AZT, 3TC, and Efavirenz to
another combination using a
protease inhibitor, demonstrated a pronounced and sustained
benefit; Efavirenz appeared to suppress
the viral load better (Manion). Other such regimens include a ddI,
d4T, and hydroxyurea
combination and Abacavir with two other nucleoside reverse
transcriptase inhibitors (NRTIs).
Both combinations have been found to be much more effective and
sustainable than dual NRTI
27
regimens (Gallant; Montaner). The second combination is
especially attractive because it involves
only one 300 mg tablet of Abacavir twice a day plus one Combivir
(AZT/3TC) tablet twice a day. A
study of this combination has shown that 71% of those on this
regimen had undetectable viral loads
at 48 weeks (Fischl).
Other protease-sparing regimens are also attractive because of
their simplicity, such as Nevirapine,
ddI and d4T; all of these drugs are taken once a day. This
combination was recently tested on eight
treatment-naive individuals with some success at 22 weeks (Pell).
Access
Because resistance to antiretroviral therapy is such a critical
issue, it is essential that individuals begin
therapy and continue treatment once begun. Access to ART is
hampered by lack of insurance
(Shapiro; Graham), which limits access to protease inhibitors
(Hecht; Celentano; Sorville) and AZT
(Solomon). The attitudes, beliefs and prejudice of some providers
toward homeless individuals may
prevent them from prescribing HAART. Research demonstrates that
African-Americans are less
likely to receive protease inhibitors (Hecht; Stone; Sorville) or
any ART (Moore; Graham; Solomon).
Active illicit drug use (Celentano), lack of enrollment in
treatment programs (Strathdee;
Solomon) and lack of continuity of care (Celentano) also
influence whether an individual will receive
ART.
It is unclear whether homeless persons are refusing ART, whether
it is not being offered to them
(Sontag), or whether they are not taking prescribed medications
when evaluated.
-
A national survey found that only 17% of homeless individuals
were taking ART, compared to 51% of housed individuals (Lieberman).
-
In San Francisco, only 7% of homeless patients were on
combination therapy at baseline (Bangsberg).
-
In Baltimore, only 8.8% of homeless injection drug users were
taking combination therapy (Celentano).
-
In New York City, only 19% of HIV-infected homeless persons
were taking AZT when it was the only drug available (Torres).
-
In Worcester, Massachusetts, only 63% of HIV-positive
individuals experiencing homelessness were prescribed AZT (Rapaport).
OI prophylaxis is an inexpensive method of preventing illness and
death that can also provide a
means of evaluating and reinforcing patient adherence patterns
before prescribing ART. Although it
is not uniformly difficult for homeless patients to obtain OI
prophylaxis, access barriers remain for
some patients because not all providers are prescribing these
medications as frequently as they
should. For example, a Boston study showed that only 82% of
homeless individuals were receiving
PCP prophylaxis (Lebow). Access to PCP prophylaxis is
particularly limited for African-Americans
(Solomon; Moore; Easterbrook) and current injection drug users
(Solomon).
Poor self-esteem and lack of desire for wellness may also impede
access to HAART and influence
treatment effectiveness. Some homeless people appear to have lost
the capacity to care because of
the systematic stigmatization and rejection they experience.
Confidentiality may be hard to maintain
because homeless individuals must spend so much time in public
and crowded spaces where it is difficult
to conceal medications and medical appointments.
28
B. Recommendations
Clinical Recommendations
1. Standards of care. Homeless people
should be treated with ART according to current guidelines,
which provide for broad discretion but do not warrant denial of
medications to individuals
who desire them.
2. Patient education. Before initiating
therapy, providers must educate patients on the following
aspects of ART:
-
Objectives and principles of antiretroviral therapy;
-
Difficulties, challenges, side effects, and intrusiveness;
-
Resistance, need for adherence, and the potential to lose
treatment options;
-
Harm reduction with nonadherence (e.g., not supplementing
therapy with antiretrovirals borrowed or purchased from others, and stopping
all medications if the patient wants or needs to stop ART).
3. Access barriers. Providers should
explore and address possible barriers to obtaining ART their
patients may face, including:
-
Lack of insurance or ADAP coverage,
-
Lack of financial resources,
-
Subsistence and transportation needs,
-
Caregiver needs,
-
Incarceration,
-
Mistrust of medical institutions or treatment, and
-
Confidentiality concerns.
4. Engagement. Successful HIV/AIDS care
requires taking the time to develop a trusting relationship
with patients; fostering a relationship prior to offering ART is
necessary for patient acceptance
of treatment.
Public Policy Recommendations
1. Formulary guidelines. National or
state formulary guidelines should be developed to allow for
increased use of antiretroviral therapy by uninsured individuals.
2. Medicaid coverage for persons with asymptomatic HIV infection.
In many states, unless a
person with HIV is eligible for welfare or supplemental security
income (SSI), or is a pregnant
woman or a child, he or she is not eligible for Medicaid, no
matter how low the individual's income
may be. Currently, a person with asymptomatic HIV infection does
not meet the SSI standard
of disability, according to which a person must have a manifest
symptom of HIV-infection
to qualify for Medicaid coverage (Westmoreland). Low-income
homeless persons with HIV infection
who do not fit into another Medicaid eligibility category often
have no access to medical
care that could prevent the onset of opportunistic illness or
further deterioration of their immune
system. Ironically, such persons become eligible for preventative
care only after they have
developed OIs or full-blown AIDS. Such a policy is unwarranted
from several points of view -
ethical, financial and epidemiological. Federal Medicaid
eligibility criteria should be broadened
to include all persons with HIV infection.
29
3. Increased coverage for HIV specialty care.
Sufficient public funding should be provided to
make antiretroviral therapy accessible to all persons living with
HIV/AIDS, regardless of their
housing or insurance status. There should be state-by-state
increases in ADAP coverage for
antiretroviral medications. Additional funding is also needed for
specialized programs, such as
Health Care for the Homeless, the Ryan White Care Act, and
Special Projects of National Significance,
which promote outreach and multidisciplinary work with
HIV-infected homeless persons.
30
VII. ADHERENCE
Pierre is a 32-year-old man living on the streets, ...referred to
our clinic from our mobile
van after requesting an HIV test. He spoke little English, having
come from Haiti
three years previously. ... He had had no medical care since his
arrival in this country.
...[Because] he often seemed distracted, ... I thought he had
psychiatric difficulties.
This belief and his lack of a stable situation - no housing, no
support from any friends
or family - made me reluctant to test. ... On examination, he had
a growth - 3 - 4
cm. in diameter, irregular, rough, erythematous, with purulence -
on the glans of his
penis. I urged him to go to our emergency room, but all he wanted
was the HIV test. I
referred him for an evaluation of the growth, which I felt was a
cancer that had become
infected. As we awaited the escort, the patient disappeared. I
thought we would
not see again.
Pierre returned to the shelter one week later. I asked if he had
gone to the hospital. He
said he had not. He was afraid because he was undocumented in
this country and did
not speak English. He asked again to be tested for HIV. ... I did
pre-test counseling,
drew blood and ... asked him to go to the emergency room to take
care of the lesion....
I received the HIV test results a week and a half later. He did
have antibodies to HIV.
I had second thoughts about what I had done. Two weeks after the
blood test, Pierre
came to the clinic and I gave him the results. He said he thought
he would be positive.
We spoke at length. ... To my surprise, he showed me a bottle of
antibiotics he had
obtained in the emergency room. He had kept his part of our
bargain.... Pierre is now
with us in the clinic receiving care.
-Elizabeth Lutas, M.D., New York, NY
A. Background
One of the most controversial issues to be addressed when
providing care for homeless individuals is
patient adherence to prescribed treatment. To avoid building
resistance to antiretroviral drugs, it is
essential for persons living with HIV to take their medication
exactly as prescribed. Individuals who
take their medications according to instructions are much more
likely to control their disease than
those who do not. Because failure to take all medications as
prescribed may cause the virus to become
resistent to one or more antiretroviral drugs, it is essential
for patients to adhere strictly to
their treatment regimens.
An 80% adherence level, considered effective for other
conditions, is not sufficient for antiretroviral
therapy (Sackett). Even brief drug holidays can lead to the loss
of viral suppression and the development
of resistance (Gallant; Katzenstein). In a recent study, 81% of
patients demonstrating
greater than 95% adherence had complete viral suppression,
compared to only 64% of those demonstrating
90% - 95% adherence (Paterson). Nonadherence rates of 40% - 50%,
reported in studies of
hypertension, asthma, psychiatric and antibiotic therapy, may not
bode well for adherence to
antiretroviral HIV/AIDS therapy (Sherer; Lerner; Sackett; Eraker;
Stephenson). Studies of nonadherence
have consistently shown that the problem is widespread,
regardless of condition or population
examined, and cannot reliably be predicted on the basis of
patient characteristics (Lerner).
The controversy about whether or not to prescribe antiretroviral
therapy to homeless persons reflects
physicians' concerns that homeless individuals may begin
treatment and, if unable to carry it
out, will develop resistance to the drugs. This would limit their
present and future treatment op-
31
tions. Nevertheless, there are no absolute contraindications for
ART or justifications to withhold
therapy from those individuals who desire it. The decision about
which treatment options to use is
subject to physician and patient discretion. Physicians must
assess each individual's likelihood to
adhere to treatment, and based on that assessment, decide what,
if any, medications to prescribe.
Adherence Assessment
Data collection from various sources may be helpful to physicians
in assessing patient adherence to
treatment. Measurement may include provider assessment,
collateral observation, subject selfassessment
through interviews and monitoring, pill counts, electronic bottle
monitors (MEMS caps),
and biological markers (Katzenstein; Blackwell; Levine). Recent
reports have demonstrated that
provider assessment alone may be no better than chance (Gilbert),
that self-reporting results in
over-estimation of ART adherence compared to more "objective"
measures (Bangsberg; Golin), and
that providers may overestimate HAART adherence in their patients
(Miller). Use of multiple
measurement techniques to assess adherence may therefore achieve
more realistic results.
An observational study from San Francisco showed that 56% of
homeless people were adherent to
ART 75% - 85% of the time (Bangsberg). In Boston, 52% of 30
patients on triple therapy were able
to achieve undetectable HIV viral loads (Lebow), and researchers
in New York found that 71% of
homeless participants on AZT claimed adherence (Torres).
Nevertheless, studies in other populations
report high rates of non-adherence: 64% (Chesney), 64% (Hecht),
67% (Samet), 42.3%
(Muma), 63% (Singh), 62% (Mostashari), and 49% (Eldred).
Reasons for Nonadherence
Some of the most common reasons given by patients for missing
doses of medication are:
-
Forgetting (Chesney; Ohmit);
-
Side effects (Samet; Broers; Ohmit);
-
Sleeping through dose (Chesney);
-
Change in routine (Chesney);
-
Feeling better (Ohmit; Richter); and
-
Fear of medications (Ohmit; Richter).
Other factors that may affect adherence include mental health and
depression (Chesney; Singh),
stress (Chesney), the need for psychiatric evaluation (Ferrando),
age (Chesney), problems taking
medications (Muma) and skepticism about them (Muma). Race is
predictive of non-adherence
(Singh; Muma; Ohmit), but it may be a surrogate for literacy with
respect to ART adherence
(Sipler). The most important considerations cited by clinicians
in deciding whether to prescribe
ART are active substance abuse (78%), access to regular food and
water (70%), side effects (69%),
active mental illness (64%), and housing status (54%) (HCH
Clinicians' Network).
Maximizing Adherence
The following factors have been shown to increase adherence:
-
Close relationship with a provider (Mostashari; Stone),
-
Close peer relationships (Mostashari),
-
Reduced pill frequency (Eldred),
-
Fitting the pill regimen into daily routine (Wenger),
32
-
Knowledge of ART action (Eldred),
-
Perceived ability to take medications (Eldred; Stone),
-
Patient belief that medications are helpful or prolong life
(Eldred; Samet),
-
Use of a medication timer (Samet).
The development of a constructive provider-patient relationship
is essential to successful antiretroviral
therapy. Cultural competence of service providers is key in
improving patient adherence to
treatment. Education of non-medical service providers in the
basic principles of ART can also help
to promote adherence. Finally, service linkages and better
communication between health care
providers and other community venues where homeless people
congregate facilitate patient followup
and assessment of ART aherence.
Public Health Considerations
The quality of life for homeless people may improve while they
are taking ART, regardless of viral or
immunologic response (Castello-Branco). Other health benefits of
treating homeless individuals
include the possibility of reducing the risk of HIV-1
transmission by decreasing the amount of virus
transmitted during exposure (Wainberg). Even partially successful
therapy can reduce blood and
genital secretion of the virus, at least theoretically resulting
in diminished risk of HIV transmission
(Wainberg). Studies have also shown that even drug resistant
viral strains may have impaired replication
competency (Goudsmit; Louder) and decreased transmissibility (Wahlberg).
The main public health concern is the possible increase of
resistant strains of HIV-1 through sexual
intercourse (Imrie; Conlon), injection drug use (de Ronde) and
perinatal transmission - to the fetus
in utero or to the infant during
breastfeeding (Colgrove). Transmission of HIV-1 variants resistant
to Lamivudine (Conway), Nevirapine (Imrie) and protease
inhibitors (Wainberg) has also been
demonstrated. A recent study detected transmission of a viral
strain that is resistant to multiple
medications, including protease inhibitors and NRTIs, from one
host to another (Hecht).
B. Recommendations
Clinical Recommendations
1. Provider education. All medical and
non-medial homeless service providers should be educated
about the basic principles of antiretroviral therapy and
adherence promotion, including
cultural sensitivity.
2. Commencement of ART. While it is
preferable to maximize stability before initiating ART,
instability is not sufficient cause to deny treatment.
3. Co-management of ART. Medical
providers should consider co-management of antiretroviral
therapy with other service providers, including case managers,
substance abuse and mental
health counselors, infectious disease specialists, shelter
providers and parole officers.
4. Identification of adherence barriers.
Providers should aggressively identify barriers to adherence,
listed below, and seek to ameliorate them.
-
Mistrust of health care, including institutions and medications
-
Lack of patient understanding of HIV/AIDS care and ART
-
Unmet subsistence needs including food, water, housing and
bathroom facilities
-
Transportation needs
-
Caregiver responsibilities and needs
-
Lack of storage facilities for medications
33
-
Loss or theft of medications
-
Inability to carry medications or limited access to them
-
Confidentiality concerns
-
Lack of peer or family support
-
Lack of fixed, dependable daily routine
-
Dependence on the schedule of others
-
Medication side effects
-
Active substance abuse
-
Mental illness and/or depression
5. Adherence promotion. Providers
should facilitate patient adherence to ART through the following:
-
Tailor the treatment regimen to the patient's lifestyle;
-
Plan ahead for changes in routine;
-
Simplify medication regimens and preserve low frequency of
dosing (BID);
-
Use organizational aids such as timer watches and pillboxes;
-
Enlist peers to reinforce and support adherence;
-
Recruit family members to lend support;
-
Institute or refer patients to day or night programs, depending
on their scheduling needs;
-
Provide on-call service or triage by personnel with a working
knowledge of ART;
-
Be available during evening and weekend hours;
-
Develop on-site food pantry, emergency meal or meal voucher
programs;
-
Provide water fountain or bottled water on-site;
-
Provide medications on-site and institute on-site medication
storage program;
-
Provide childcare at clinics; and
-
Identify housing options.
5. Incentives for treatment. Providers
should consider the use of monetary or other incentives to
improve attendance to follow-up visits and ART success.
6. Aggressive outreach. Outreach teams
and personnel should be employed to:
-
Increase follow-up visits by providing reminders and
transportation;
-
Identify and address barriers to adherence at various locations
and facilities;
-
Conduct pill counts and adherence evaluations;
-
Reinforce treatment goals and the need for adherence;
-
Provide medications to individuals who may run out; and
-
Provide food or water.
7. Adherence assessment. Providers
should evaluate their patients' history of adherence with
other medications. Once ART is begun, providers should do
adherence assessments at every
clinical visit and provide the means to increase adherence.
Public Policy Recommendations
1. Provider education. Mainstream
providers should be educated about identifying homeless patients
and addressing their unique treatment needs.
2. Service linkages. All jurisdictions
should encourage linkages among health care facilities, service
providers and correctional institutions.
34
VIII. RESEARCH
M. A. is a 45-year-old woman with a history of HIV disease, ...
depression, hepatitis C, a
long-standing narcotic addiction, amenorrhea, [and] chronic
low-back pain ... status postlaminectomy.
...She had applied for SSI, but was declined; she is now
appealing. She is a
sex worker and receives general assistance. She has two children,
six and seven years old,
who are in foster care. Shortly after she found out that she was
HIV positive, M. A. came
to the clinic to establish primary care for her HIV disease. At
that time she had no specific
complaints, but was interested in methadone maintenance treatment
for her narcotic
addiction. Her viral load was about 46,000, and her initial CD4
count was 576. ... It
quickly became obvious that she was unable to commit to therapy.
She seemed distracted
by a number of needs; for example, she needed a letter for her
SSI application, and she
needed another letter in order to receive methadone maintenance.
She did not have stable
housing, and she had so many other priorities that taking
medication on a regular basis
was not one of them. ... When I saw her most recently, however,
M. A. expressed interest
in HIV treatment, feeling that if she does not get treatment she
will die, and she is
not ready to die. I prescribed Combivir and Nevirapine, hoping to
get her started without
using protease inhibitors. I am uncertain that M. A. is able to
adhere, so I am retaining
the possibility of using protease inhibitors in the future.
-Karen Bayle, M.D., San Francisco, California
A. Background
The research literature on HIV/AIDS and homelessness, though
sparse, clearly identifies barriers to
prevention, health care access and treatment faced by homeless
people living with HIV, and points
to a number of areas where more investigation is needed. More
targeted studies employing standardized
methodologies are needed to form a scientific basis for the
development of successful
HIV/AIDS prevention and treatment strategies for people who lack
stable housing. Such research is
warranted by the preliminary evidence, reported here, that
HIV/AIDS has a disproportionate effect
on particular homeless subpopulations, and that HIV-infected,
housed persons are at increased risk
of becoming homeless. Failure to measure the scope of HIV/AIDS
within the homeless population
and to develop well-tested prevention and treatment strategies is
likely to exacerbate the serious
public health problem which the human immunodeficiency virus and
its devastating sequelae already
present.
Relatively few clinical or epidemiological data exist on HIV
prevention and treatment for homeless
individuals, in part because of limited resources to study
medical conditions in this population. At
the same time, there is a great need for behavioral and clinical
research on particular homeless subgroups,
to form a scientific basis for the development of successful
prevention strategies and treatment
protocols. Finally, there is a need for policy research to
further document and address system
barriers to HIV prevention and care for homeless people.
Needs Assessment
The current standard of care for HIV prevention and risk
reduction requires a needs assessment of
targeted populations and the tailoring of interventions to the
populations' demonstrated needs.
Needs assessments of particular homeless populations should
specify barriers to HIV prevention and
services experienced by different cultural and linguistic groups
in different geographical areas.
35
Priorities
Additional research is needed to develop and test strategies to
decrease HIV transmission among
homeless persons, and to identify those who are infected for
treatment. Research to identify individual
characteristics that may increase adherence to antiretroviral
therapy is also essential. Absent
objective data, clinicians must rely on their own subjective
perceptions in deciding whether to prescribe
ART. Given their poor track record in predicting patient
adherence (Gilbert), there may be
better ways to select patients for and encourage their adherence
to treatment.
B. Recommendations
Epidemiology
-
General. Better characterization of the extent of
HIV/AIDS among homeless people, and of the extent of homelessness among
persons with HIV/AIDS.
-
Specific. Better characterization of the extent of
HIV/AIDS in various subpopulations - e.g., rural populations, homeless women,
transgendered individuals, etc. Determine the incidence, prevalence and
natural history of HIV/AIDS within these subpopulations.
Behavioral Research
-
Behavioral change. Develop better methodologies to
evaluate behavioral change in people without stable homes.
-
HIV prevention. Investigate high-risk behaviors. Develop
and implement HIV prevention strategies for homeless men and women in targeted
subpopulations.
-
Testing, notification and adherence. Identify barriers
for homeless persons to HIV testing and counseling, notification of test
results and treatment. Develop and test interventions that improve rates of
HIV testing, notification and adherence to treatment.
-
ART. Identify effective ways to reduce barriers to
antiretroviral therapy for homeless people and to increase ART utilization.
Clinical Research
-
Co-morbidities and nutritional deficiencies. Measure the
impact of co-morbidities and nutritional deficiencies on HIV/AIDS progression.
-
Immunization rates. Quantify immunization rates for
homeless people with HIV/AIDS, including completion rates for hepatitis B
immunizations. Design and evaluate interventions to increase immunization
rates.
-
Outcomes. Determine the outcomes of antiretroviral
therapy among homeless people.
Policy Research
-
Impact of health coverage. Determine the effect of
Medicaid enrollment on homeless peoples' access to care
and health status.
-
Health care access. Describe system barriers to health
care access for particular homeless subpopulations.
Based on these data, develop strategies to increase access to
comprehensive health
36
care for all homeless people.
Appendix I - REFERENCES
-
Abdul-Quader AS, Tross S, Friedman SR, et al. Street-recruited
intravenous drug users and sexual risk reduction in New York City. AIDS
1990;4: 1075-1079.
-
ACLU AIDS Project. HIV and homelessness. October 1999: 1-15.
-
Acquaviva KD. Philadelphia metropolitan region housing needs
assessment of people living with HIV and AIDS: data for a priority setting.
Philadelphia, PA: Unpublished, 1998.
-
Adult Health Services, Portland Public Health Division.
Community plan for comprehensive services for individuals with HIV infection
whose functioning is impaired by mental illness and/or substance abuse.
Portland, ME: 1998.
-
AIDS Housing Corporation, Latino Health Institute. A needs
assessment of HIV/AIDS housing in Boston, Massachusetts. Boston, MA: City of
Boston, 1998.
-
Allen DM et al. HIV infection among homeless adults and runaway
youth, United States, 1989-1992. AIDS 1994;8: 1593-1598.
-
Alwood K, Keruly J, Moore-Rice K et al. Effectiveness of
supervised, intermittent therapy for tuberculosis in HIV-infected patients.
AIDS 1994;8: 1103-1108.
-
Anderson JR. Clinical care of women: recent developments.
HRSA Care Action December 1998: 4-7.
-
Anderson JR. Report from Geneva: Women and HIV. The Hopkins
HIV Report. Baltimore, MD: July 1998.
-
Arno PS et al. The impact of housing status on health care
utilization among persons with HIV disease. Journal
of Health Care for the Poor and Underserved 1996;7:
36-49.
-
Bagasra O, Steiner RM, Ballas SK et al. Viral Burden and
disease progression in HIV-1-infected patients with sickle cell anemia.
American Journal of Hematology 1998;59: 199-207.
-
Bangsberg D, et al. Protease inhibitors are associated with
viral load suppression in HIV+ homeless and marginally housed (H/M) adults.
In: Program and abstracts of the 12th World AIDS Conference; Geneva,
Switzerland: June 28-July 3, 1998. Abstract 32390.
-
Bangsberg D, et al. Protease inhibitors in the HIV+ homeless
and marginally housed: good adherence but rarely prescribed. In: Program
and abstracts of the 12th World AIDS Conference; Geneva, Switzerland: June
28-July 3, 1998. Abstract 32406.
-
Bangsberg D, Tulsky DP, Hecht FM, Moss AR. Protease inhibitors
in the homeless. Journal of the American Medical
Association 1997;278:63-65.
-
Bangsberg DR, Hecht FM, Charlebois EC, et al. Spontaneous
adherence (ADH) adits (SAA) predicts viral suppression in the REACH cohort.
In: Program and Abstracts of the Sixth Conference on
Retroviruses and Opportunistic Infections; Chicago,
Ill. Abstract 93.
-
Bangsberg, David. Personal communication. San Francisco, CA:
1999.
37
-
Barnes PF, El-Hajj H, Preston-Martin S, et al. Transmission of
tuberculosis among the urban homeless. Journal of the
American Medical Association 1996;275: 305-307.
-
Barry M, Fleck E, Lentz S et al. "Medicine on wheels": An
opportunity for outreach and housestaff education. Connecticut Medicine
1994;58: 535-539.
-
Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus
Zidovudine compared with Zalcitabine plus Zidovudine in patients with HIV
infection: A randomized, double-blind, placebo-controlled trial. Annals of
Internal Medicine 1996;125: 161-172.
-
Bartlett JG, Volberding P, et al. National HIV/AIDS Treatment
Survey. Unpublished: 1999.
-
Bartlett JG. Medical Management of HIV Infection 1998.
Baltimore, MD: Port City Press, 1998.
-
Bassuk EL, Rubin L, Lauriat AS. Characteristics of sheltered
homeless families. American Journal of Public Health
1986;76: 1097-1101.
-
Bayer R, Stryker J. Ethical challenges posed by clinical
progress in AIDS. American Journal of Public Health
1997; 87: 1599-1602.
-
Beardsley M, Clatts MC, et al. Homelessness and HIV-risk
behaviors in a sample of New York City drug injectors. AIDS and Public
Policy Journal 1992;7: 162-171.
-
Becker S. Adherence is not just for patients: Do clinicians
follow treatment guidelines. Updates From Geneva,
Healthcare Communications Group, L.L.C. 1998.
-
Berger TG. Dermatologic care in the AIDS patient. In: Sande MA,
Volberding PA ed. The Medical Management of AIDS.
Philadelphia, PA: W.B. Saunders Co, 1995: 216-217.
-
Berry DE, McKinney MM, McClain M, Valero-Figueira E.
Rural HIV Service Networks: Patterns of Care and Policy Issues.
Rockville, MD: HRSA, 1995.
-
Berry DE, McKinney MM, McClain M. Rural HIV service networks:
patterns of care and policy issues. AIDS and Public
Policy Journal 1996;11: 36-46.
-
Besch CL, Morse E, Simon P et al. Preliminary results of a
compliance study within CPCRA 007 combination nucleoside study (NuCombo). 4th
Conference on Retroviruses and Opportunistic Infections 1997;11: Abst 254.
-
Besch CL. Compliance in clinical trials. AIDS 1995;9:
1-10.
-
BETA home page. Adherence and the HIV community. January 1998
-
Bloch AB, Cauthen GM, Onorato IM et al. Nationwide survey of
drug-resistant tuberculosis in the United States. Journal of the American
Medical Association 1994;271: 665-671.
-
Bluthenthal RN, Kral AH, et al. Use of an illegal syringe
exchange and injection-related risk behaviors among street-recruited injection
drug users in Oakland, California, 1992 to 1995.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
1998;18: 505-511.
-
Bonuck KA, Arno PS. Social and medical factors affecting
hospital discharge of persons with HIV/AIDS. Journal of Community Health
1997;22: 225-232.
-
Breakey WR, Fischer PJ, Kramer M, et al. Health and mental
problems of homeless men and women in Baltimore. Journal of the American
Medical Association 1989;262: 1352-1357.
38
-
Breakey WR, Fischer PJ. Homelessness: The extent of the
problem. Journal of Social Issues 1990;46: 31-47.
-
Breakey WR. Mental health services for homeless people. In:
Robertson MJ and Greenblatt M ed. Homelessness: A
National Perspective. New York: Plenum Press, 1992:
p. 101-107.
-
Brickner PW, et al. Providing health services for the homeless:
a stitch in time. Bulletin of the New York Academy of
Medicine 1993;70: 146-169.
-
Brickner PW, Scanlan BC, Conanan B, et al. Homeless persons and
health care. Annals of Internal Medicine
1986;104: 405-409.
-
Broers B, Morabia A, Hirschel B. A cohort study of drug users'
compliance with Zidovudine treatment. Archives of
Internal Medicine 1994;154: 1121-1127.
-
Brudney K, Dobkin J. Resurgent tuberculosis in New York City.
American Review of Respiratory Diseases
1991;144: 745-749.
-
Burman WJ, Cohn DL, Rietmeijer CA, et al. Noncompliance with
directly observed therapy for tuberculosis. Chest
1997;111: 1168-73.
-
Burman WJ, Cohn DL, Rietmeijer CA, et al. Short-term
incarceration for the management of noncompliance with tuberculosis treatment.
Chest 1997;112: 57-62.
-
Burt M, Cohen B. America's Homeless: Numbers,
Characteristics, and Programs that Serve Them. Urban Institute 1989.
-
Burt MR. Homelessness: definitions and counts. In: Baumohl J,
ed. Homelessness in America. Phoenix, AZ: Oryx Press, 1996: 15-23.
-
Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral
therapy for HIV infection in 1997: Updated recommendations of the
international AIDS Society-USA panel. Journal of the
American Medical Association 1997;277: 1962-1969.
-
Castello-Branco LRR, et al. AIDS therapy in Brazil. Nature
1998;392: 431.
-
Catt S, Stygal J, Catalan J. Acceptance of Zidovudine (AZT) in
early HIV disease: the role of health beliefs. AIDS CARE 1995;7:
229-234.
-
CDC. Community-Based HIV prevention in presumably underserved
populations - July-September 1995. Journal of the American Medical
Association 1997;277: 876.
-
Centers for Disease Control and Prevention (CDC). HIV/AIDS
Surveillance Report, 10(2), Year-end Report, 1998.
-
CDC. HIV/AIDS Surveillance Report, 9(1): 1997.
-
CDC. Surveillance of tuberculosis and AIDS co-morbidity -
Florida, 1981-1993. MMWR 1996;45: 38-41
-
CDC. Tuberculosis among homeless shelter residents. MMWR
1991;40: 869-877.
-
Celentano D. Personal communication. ALIVE study. Baltimore,
MD: 1999.
-
Celentano DD, Vlahov D, Cohn S, et al. Risk factors for
shooting gallery use and cessation among intravenous drug users. American
Journal of Public Health 1991;81: 1291-1295.
39
-
Celentano DD, Vlahov D, et al. Self-reported antiretroviral
therapy in injection drug users. Journal of the
American Medical Association 1998;280: 544-546.
-
Chesney MA. New antiretroviral therapies: adherence challenges
and strategies. Healthcare Communications Group, L.L.C., 1998.
-
Clatts MC, Beardsley M, et al. Homelessness and risk behavior
among U.S. drug injectors: Implications for prevention policy. In: Program
and abstracts of the 8th International Conference on AIDS; Amsterdam, The
Netherlands: July 19-24, 1992. Abstract # PoD 5354.
-
Cohen OR and Fauci AS. Transmission of multidrug-resistant
human immunodeficiency virus - the wake-up call. New England Journal of
Medicine 1998; 339:341-343.
-
Cohn SE, et al. Adults under care for HIV in rural areas of the
United States. Unpublished manuscript: 1998.
-
Cohn SE, et al. The geography of AIDS: patterns of urban and
rural migration. Southern Medical Journal
1994;87:599-606.
-
Colgrove R, et al. Selective vertical transmission of HIV-1
Zidovudine resistant mutations. In: Program and
abstracts of the 5th Conference on Retroviruses and Opportunistic Infections;
Chicago, Ill: February 1-5. Abstract 265.
-
Comerford M, et al. Association between former place of
residence and serostatus of IVDUs in South Florida. In: Program and
abstracts of the 5th International Conference on AIDS; Montreal, Canada:
June 4-9, 1989. Abstract # T.A.P.46.
-
Committee on Health Care for Homeless People. Homelessness,
Health, and Human Needs. Institute of Medicine. Washington, D.C.: National
Academy Press,1988.
-
Conlon CP, Klenerman P, et. al. Heterosexual transmission of
human immunodeficiency virus type 1 variants associated with Zidovudine
resistance. Journal of Infectious Disease 1994;169: 411-415
-
Conviser R. Evaluating how housing contributes to health for
people living with HIV. Presented: Second National HIV/AIDS Housing
Conference. Seattle, WA: August 1996.
-
Corby NH, et al. HIV serostatus and risk behaviors of street
IVDUS. In: Program and abstracts of the 5th
International Conference on AIDS; Montreal, Canada:
June 4-9, 1989. Abstract # T.A.P.42
-
Cramer J, Mattson RH, Prevey ML, et al. How often is medication
taken as prescribed? Journal of the American Medical
Association 1989;261: 3273-3277.
-
Crandall SJS, Volk RJ, Loemker V. Medical students' attitudes
toward providing care for the underserved: are we training responsible
physicians? Journal of the American Medical
Association 1993;269:2519-2523.
-
Cunningham WE, et al. Access to medical care and health-related
quality of life for low-income persons with symptomatic human immunodeficiency
virus. Medical Care 1995;33: 739-754.
-
Cunningham WE, et al. The prospective effect of access to
medical care on health-related quality-of life outcomes in patients with
symptomatic HIV disease. Medical Care 1998;36: 295-306.
-
Cunningham WE, et al. The impact of competing needs for basic
subsistence on access to medical care for persons with HIV receiving care in
the United States. Journal of General Internal
Medicine
40
1998;13(supp):60.
-
Davis K, Cameron B, Stapleton JT. The impact of HIV patient
migration to rural areas. AIDS Patient Care
1992;6:225-228.
-
De Ronde, et al. First case of new infection with Zidovudine-resistant
HIV-1 among prospectively studied intravenous drug users and homosexual men in
Amsterdam. AIDS 1996;10: 231-232.
-
DeCarlo P, Susser E, Tulsky JP. What are homeless people's HIV
prevention needs? HIV In-Site. Prevention.
-
Deeks SG. Smith M, Holdniy M, Kahn JO. HIV-1 protease
inhibitors: A review for clinicians. Journal of the
American Medical Association 1997;277: 145-153.
-
Dennis DL, Levine IS, Osher FC. The physical and mental health
status of homeless adults. Draft: Fannie Mae Annual Housing Conference 1991.
-
Detels R, Munoz A, et. al. Effectiveness of potent
antiretroviral therapy on time to AIDS and death in men with known HIV
infection duration. Journal of the American Medical Association
1998;280: 1497-1503.
-
Dieterich DT. What are the potential interactions and clinical
management problems of patients who are co-infected with HIV and chronic
hepatitis? 8th Clinical Options in HIV Symposium on Hepatitis and HIV,
Medscape HIV/AIDS 4(2), 1998 (www.medscape.com).
-
Easterbrook PJ, et. al. Racial and ethnic differences in
outcome in Zidovudine-treated patients with advanced HIV disease. Journal
of the American Medical Association 1991;266: 2713-2718
-
El-Bassel N, Schilling R, et al. Correlates of sex trading
among female drug users in Harlem. In: Abstracts International Conference on
AIDS PoC 4658.
-
El-Bassel N, Schilling RF, et al. Sex trading and psychological
distress among women recruited from the streets of Harlem. American Journal
of Public Health 1997;87: 66-70.
-
El-Sadr W, Medard F, et al. Directly observed therapy for
tuberculosis: the Harlem Hospital experience, 1993. American Journal of
Public Health 199686: 1146-1149.
-
Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to
antiretroviral and pneumocystis prophylaxis in HIV disease.
Journal of Acquired Immune Deficiency Syndromes and Human
Retrovirology 1998;18: 117-125.
-
Eraker SA, Kirscht JP, Praker MH. Understanding and improving
patient compliance. Annals of Internal Medicine
1984;100: 258-268.
-
Erickson JR, Stevens S, Estrada A. Risk for HIV among homeless
male and female intravenous drug users (IDUs) in the United States. In:
Abstracts International Conference on AIDS PoC 4317.
-
Eron J. Efavirenz and the prospect for protease sparing.
Updates From Geneva 1998.
-
Ferrando SJ, Wall TL, Batki SL, Sorenson JL. Psychiatric
morbidity, illicit drug use and adherence to Zidovudine (AZT) among injection
drug users with HIV disease. American Journal of Drug
and Alcohol Abuse 1996;22: 475-487.
-
Fischer PJ, Breakey WR. The epidemiology of alcohol, drug, and
mental disorders among homeless
41
persons. American Psychologist 1991;46: 1115-1128.
-
Foster CD, ed. Homeless in America. Wylie, TX:
Information Plus, 1993.
-
Fournier A, et al. Human Immunodeficiency Virus among the
homeless in Miami: a new direction for the HIV epidemic. American Journal
of Medicine 1996;100: 582-584.
-
Gallagher TC, et al. Determinants of regular source of care
among homeless adults in Los Angeles. Medical Care
1997;35: 814-830.
-
Gallant J. Antiretroviral therapy-resistance: the Lago Maggiore
meeting, and more. In: Updates From Geneva,
Healthcare Communications Group, L.L.C. 1998
-
Gallant JE, Murphy R. Antiretroviral Therapy. Medical Education
Collaborative. Medscape.com. Golden, CO: Dec 24, 1998.
-
Garfein RS, Doherty MC, et al. Prevalence and incidence of
hepatitis C virus infection among young adult injection drug users.
Journal of Acquired Immune Deficiency Syndromes and Human
Retrovirology 1998;18(Supp 1): S11-S19.
-
Gelberg L, et al. Competing priorities as a barrier to medical
care among homeless adults in Los Angeles. American
Journal of Public Health 1997;87: 217-220.
-
Gelberg L, Doblin BH, Leake BD. Ambulatory health services
provided to low-income and homeless adult patients in a major community health
center. Journal of General Internal Medicine 1996;11: 156-162
-
Gelberg L, Linn LS, Leake BD. Mental health, alcohol and drug
use, and criminal history among homeless adults. American Journal of
Psychology 1988; 145: 191-196.
-
Gelberg L, Linn LS. Assessing the physical health of homeless
adults. Journal of the American Medical Association
1989;262: 1973-1979.
-
Gerbert B, et al. Dilemmas surrounding prescribing
protease-inhibitor therapies: Providers reports of practices with their HIV-seropositive
patients. Journal of General Internal Medicine 1998;13(supp):71.
-
Gerbert B, Maguire BT. Primary care physicians and AIDS:
Attitudinal and structural barriers to care. Journal of the American
Medical Association 1991;266: 2837-2842
-
Gillis L. Personal communication. Baltimore, MD, 1999.
-
Goldfinger SM, et al. HIV,
Homelessness, and Serious Mental Illness: Implications for Policy and
Practice. Delmar, NY: National Resource Center on
Homelessness and Mental Health, March 1998.
-
Gollub EL, Trino R, et al. Co-occurrence of AIDS and
tuberculosis: Results of a database "match" and investigation. Journal of
Acquired Immune Deficiency Syndromes and Human Retrovirology 1997; 16:
44-49.
-
Gordin FM, Nelson ET, Matts JP, et al. The impact of human
immunodeficiency virus infection on drug-resistant tuberculosis. American
Journal of Research in Critical Care Medicine 1996;154: 1478-1483.
-
Goulart M, Madover S. An AIDS prevention program for homeless
youth. Journal of Adolescent Health
1991; 12: 573-575
42
-
Graham NMH, et al. Access to therapy in the multicenter AIDS
cohort study, 1989 - 1992. Journal of Clinical
Epidemiology 1994; 1003-1012.
-
Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs.
sequential initiation of therapy with Indinavir, Zidovudine, and Lamivudine
for HIV-1 infection: 100 week follow-up. Journal of
the American Medical Association 1998;280: 35-41.
-
Gulick RM, Mellors JW, Havlir D, et al. Treatment with
Indinavir, Zidovudine, and Lamivudine in adults with human immunodeficiency
virus infection and prior antiretroviral therapy. New
England Journal of Medicine 1997;337: 734-739.
-
Hagerty CA and O'Connell JJ. Evaluating the outcomes of a
linkage system designed to facilitate access for chronically homeless persons
to an outpatient AIDS program. In: Abstracts International Conference on AIDS
B. 506.
-
Hahn J, Shafer K, Moss AR. High rate of HIV infection in
homeless young injectors: Sex poses greatest risk. In: Program and
abstracts of the 12th World AIDS Conference; Geneva, Switzerland: June
28-July 3, 1998. Abstract 23233.
-
Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of
two nucleoside analogues plus Indinavir in persons with human immunodeficiency
virus infection and CD4 cell counts of 200 per cubic millimeter or less.
New England Journal of Medicine 1997;337: 725-733.
-
Harper G, Butler MC. Context affects homeless/runaway youths'
HIV sexual risk. In: Program and abstracts of the
12th World AIDS Conference; Geneva, Switzerland:
June 28-July 3, 1998. Abstract 23517.
-
Hartz D, Banys P, Hall SM. Correlates of homelessness among
substance abuse patients at a VA medical center. Hospital and Community
Psychology 1994; 45: 491-493.
-
Harvey JC. The ethics of AIDS care.
Journal of the International Association of Physicians in AIDS Care
1997:3: 21-42.
-
Haynes RB, McKibbon KA, Kanani. Systematic review of randomized
trials of interventions to assist clients to follow prescriptions for
medications. Lancet 1996;348: 383-386.
-
Haynes RB, Sackett DL, Taylor DW. How to detect and manage low
patient compliance in chronic illness. Geriatrics 1980;35: 91-97.
-
HCH Clinician's Network. HCH Clinician's Survey. Nashville, TN:
Unpublished, 1999.
-
Hecht FM, et al. Insurance and race predict access to HIV
protease inhibitors. Journal of General Internal
Medicine 1998;13(supp): 46.
-
Hecht FM, Grant RM, Petropoulous CJ, et al. Sexual transmission
of an HIV-1 variant resistant to multiple reverse-transcriptase and protease
inhibitors. New England Journal of Medicine 1998;339: 307-312.
-
Hecht FM, Kessler H, Fletcher C, et al. HIV Infection in the
HAART Era. Proceeds of precourse. Society of General Internal Medicine
National Meeting. Chicago, IL: April 1998.
-
Hibbs JR, Benner L. Mortality in a cohort of homeless adults in
Philadelphia. New England Journal of Medicine
1994;331: 304-309.
43
-
HIV/AIDS Bureau. Women and HIV/AIDS. Washington, D.C.:HRSA Care
Action, Dec1998;5:1-3.
-
Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths
from AIDS due to new antiretrovirals. Lancet
1997;349: 1294.
-
Hudson RA, et al. Adolescent runaways' behavioral risk factors,
knowledge about AIDS and attitudes about condom use. In: Program and
abstracts of the 5th International Conference on AIDS; Montreal, Canada:
June 4-9, 1989. Abstract # T.D.P.11.
-
Hwang, et al. Risk factors for death in homeless adults in
Boston. Archives of Internal Medicine
1998;158: 1454-1460.
-
Hwang SW, Orav EJ, O'Connell JJ, Lebow JM, and Brennan TA.
Causes of death in homeless adults in Boston. Annals of Internal Medicine
1996;126: 625-628.
-
Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: a
framework for clinical research and clinical care. Journal of Clinical
Epidemiology 1997;50: 385-391.
-
Imrie A, et al. Transmission of Human Immunodeficiency Virus
Type 1 Resistance to Neviapine and Zidovudine. Journal of Infectious
Disease 1997;175: 1502-1506.
-
Johnson TP, Aschkenasy JR, et al. Self-reported risk factors
for AIDS among homeless youth. AIDS Education and
Prevention 1996; 8: 308-322.
-
Kaplan A, Golin C, Beck K, et al. Adherence to protease
inhibitor therapy and viral load. In: Program and
Abstracts of the Sixth Conference on Retroviruses and Opportunistic Infections;
Chicago, Ill. Abstract 96.
-
Kaplan JE, Masur H, Jaffe HW, Holmes KK. Preventing
opportunistic infections in persons infected with HIV: 1997 Guidelines.
Journal of the American Medical Association 1997;278: 337-338.
-
Katz M. Access to Therapy - Look into their eyes.and don't look
away. In: Updates From Geneva, Healthcare Communications Group, L.L.C.
1998.
-
Katz MH, Cunningham WE, Mor V. Prevalence and predictors of
unmet needs for non-medical services among HIV-infected persons receiving
medical care in the United States: relationship to case management. Journal
of General Internal Medicine 1998;13(supp): 48.
-
Katzenstein DA, Lyons C, Molaghan JP, et al. HIV therapeutics:
Confronting adherence. Journal of the Association of
Nurses in AIDS Care 1997;8(Supp): 46-58.
-
Katzenstein DA. Adherence as a particular issue with protease
inhibitors. Journal of the Association of Nurses in
AIDS Care 1997;8(Supp): 10-17.
-
Keenan L, Lieberman B. Needs assessment study determines risk
factors for homelessness among people with HIV. AHCPR newsletter.
Washington, D.C.: 1998;217: 18
-
Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians'
experience with the acquired immunodeficiency syndrome as a factor in
patients' survival. New England Journal of Medicine 1996;334: 701-706.
-
Koegel P, Burham MA, Baumohl J. The causes of homelessness. In:
Baumohl J, ed. Homelessness in America.
Phoenix, AZ: Oryx Press, 1996: 31.
-
Koegel P, Burnam MA. Alcoholism among homeless adults in the
inner city of Los Angeles. Archives
44
of General Psychiatry 1988; 45:
1011-1018.
-
Koehler JE, et al. Molecular epidemiology of bartonella
infections in patients with bacillary angiomatosis-peliosis. New England
Journal of Medicine 1997;337: 1876-1883.
-
Kouzi A, Des Jardins DC. Determinants of contraceptive
practices among intravenous drug users in New York City. In: Program and
abstracts of the 5th International Conference on AIDS; Montreal, Canada:
June 4-9, 1989. Abstract # Th.E.P.4.
-
Kuritzkes D, Mellors J. Antiretroviral therapy: Resistance. 8th
Clinical Care Options for HIV Symposium. 1998. Healthcare Communications
Group, L.L.C. 1998.
-
Lebow J and Graziani C. Combination antiretroviral use and
system level outcome in the homeless of Boston. Boston, MA: Unpublished
manuscript, 1998.
-
Lebow J, et al. Initial presentation of HIV-infected homeless
persons for primary medical care. In: Abstracts International Conference on
AIDS PoD5734.
-
Lebow JM, O'Connell JJ, Oddleifson S, et al. AIDS among the
homeless of Boston: A cohort study. Journal of
Acquired Immune Deficiency Syndromes and Human Retrovirology
1995;8: 292-296.
-
Lerner BH, Gulick RM, Dubler NN. Rethinking nonadherence:
historical perspectives on triple-drug therapy for HIV disease. Annals of
Internal Medicine 1998;129: 573-578.
-
Lerner BH. Temporarily detained: tuberculosis alcoholics in
Seattle, 1949 through 1960. American Journal of
Public Health 1996;86: 257-265.
-
Levine AM. Adherence to antiretroviral therapy. In: Updates
From Geneva, Healthcare Communications Group, L.L.C. 1998.
-
Levine AM. Adherence update. In: Updates From Geneva,
Healthcare Communications Group,
-
L.L.C. 1998.
-
Lieberman B. The state of AIDS housing of America. AIDS Housing
of Washington. Presented at: Third National HIV/AIDS Housing Conference,
Atlanta, GA 1998.
-
Link BG, Susser E, Stueve A, et al. Lifetime and five-year
prevalence of homelessness in the United States. American Journal of Public
Health 1994; 84: 1907-1912.
-
Low G, et al. A report on housing for persons living with
HIV/AIDS in the city and the county of Los Angeles. Los Angeles, CA:Shelter
Partnership, Inc. Jan 1999.
-
Lyman A. Prescribing protease inhibitors for the homeless.
Journal of the American Medical Association
1997; 278: 1235-1236.
-
Lyons C. HIV Drug adherence: special situations.
Journal of the Association of Nurses in AIDS Care
-
1997;8(Supp): 29-36.
-
Maimous AG, Neill RA, Matheny SC. Frequency of human
immunodeficiency virus testing among rural U.S. residents and why it is done.
Archives of Family Medicine 1995;4: 41-45.
-
Mangino JE, Fass RJ. Inclusion of women in clinical trials of
antiretroviral agents for HIV/AIDS during pregnancy. Lancet 1997;350:
150.
-
Marwick C. HIV/AIDS care calls for reallocation of resources.
Journal of the American Medical Asso-
45
ciation 1998; 279: 491-492.
-
Marwick C. The 'sizable' homeless population: a growing
challenge for medicine. Journal of the American
Medical Association 1985;253: 3217-3225.
-
McArthur J. Neurology update. The Hopkins HIV Report
March 1999;11: 8.
-
McCormack D, Gooding BA. Homeless persons communicate their
meaning of health. Canadian Journal of Nursing
Research 1993;25: 33-50.
-
McKinney MM (Ed.) Rural HIV/AIDS: issues in prevention and
treatment. Proceedings of: Southeastern Conference on
Rural HIV/AIDS. Atlanta, GA, 1997.
-
McKinney MM. HIV/AIDS Among Rural Women: Service Networks
and Unmet Needs. Rockville, MD: HRSA, 1996.
-
McKinney MM. Service needs and networks of rural women with
HIV/AIDS. AIDS Patient Care and STDs
1998;12: 471-480.
-
McMurray-Avila M. Organizing Health Services for Homeless
People: A Practical Guide. Nashville, TN: National Health Care for the
Homeless Council 1997.
-
Mehta S, Moore RD, Graham NMH. Potential factors affecting
adherence with HIV therapy. AIDS
1997;11: 1665-1670.
-
Miller L, Liu H, Beck K, et al. Providers' estimates of
adherence overestimate reports from Medication Event Monitoring System (MEMS)
for patients on protease inhibitors (PIS). In:
Program and Abstracts of the Sixth Conference on Retroviruses and
Opportunistic Infections; Chicago, Ill. Abstract 97.
-
Montaner JSG, Hogg R, Raboud J, et al. Antiretroviral treatment
in 1998. Lancet 1998;352: 1919-1922.
-
Moore RD, et al. Racial differences in the use of drug therapy
for HIV disease in an urban community. New England
Journal of Medicine 1994;330: 763-768.
-
Morris JT, McAllister C. Homeless individuals and
drug-resistant tuberculosis in south Texas. Chest
1992;102: 802-804.
-
Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and
adherence with antiretroviral therapy among HIV-infected women in a
correctional facility. Journal of Acquired Immune
Deficiency Syndromes and Human Retrovirology
1998;18: 341-348.
-
Muma RD, Ross MW, Parcel GS, Pollard RB. Zidovudine adherence
among individuals with HIV infection. AIDS CARE 1995;7: 439-447.
-
National Coalition for the Homeless. Addiction disorders and
homelessness. NCH Fact Sheet #6 Oct 1997.
-
National Coalition for the Homeless. How many people experience
homelessness? NCH Fact Sheet #2. January 1997.
-
National Health Care For the Homeless Council, Inc. Annual
Report 1998. Nashville, TN: 1998.
-
National Health Care for the Homeless Council, Inc.
Combating Tuberculosis and Homelessness: Recommendations for Policy and
Practice. Nashville, TN: Nat HCH Council 1994.
46
-
National Rural Health Association. HIV/AIDS in Rural America.
Kansas City, MO: 1997.
-
National Rural Health Association. The Rural Homeless:
America's Lost Population. Kansas City, MO: 1996.
-
Nazar-Stewart V, Nolan CM. Results of a directly observed
intermittent Isoniazid preventive therapy program in a shelter for homeless
men. American Review of Respiratory Disease 1992146: 57-60.
-
Neville K, Bromberg A, Bromberg R, et al. The third epidemic-
multidrug-resistant tuberculosis. Chest
1994;105: 45-48.
-
New York State AIDS Advisory Council. Report of the Ethical
Issues in Access to HIV Treatment Workgroup. New York, NY: Sept 1998.
-
Nyamathi, AM, Flaskerud J, et al. Evaluation of two AIDS
education programs for impoverished Latina women. AIDS Education and
Prevention 1994; 6: 296-309.
-
O'Connell J, Lozier J, Gingles K.
Increased Demand and Decreased Capacity: Challenges to the McKinney Act's
Health Care for the Homeless Program. Nashville, TN:
National Health Care for the Homeless Council 1997.
-
O'Connell JJ, Lebow J. AIDS and the homeless of Boston. New
England Journal of Public Policy 1991;
-
541-555.
-
O'Connor PG, Selwyn PA, Schoottenfeld RS. Medical care for
injection drug users with human immune deficiency virus infection. New
England Journal of Medicine 1994;331: 450-451.
-
Oakley D, Dennis DL. Responding to the needs of homeless people
with alcohol, drug, and/or mental disorders. In: Baumohl J, ed.
Homelessness in America. Phoenix, AZ: Oryx Press, 1996: 180-185.
-
Odem S, Sorvillo F, et al. The prescription of protease
inhibitors among women with AIDS in Los Angeles County. National Conference on
Women and HIV 1997. Abstract no. 304.5, 1997.
-
Odem S, Sorvillo F, Kerndt P, et al. The prescription of
protease inhibitors among women with AIDS in Los Angeles County. National
Conference on Women and HIV. Abstract no. 304.5, 1997.
-
Ohmit S, Schuman P, Schoenbaum E, et al. Adherence to
antiretroviral therapy among women in the HIV Epidemiology Research Study
(HERS) and Women's Inter-Agency HIV Study (WIHS). In:
Abstracts, 12th International Conference on AIDS.
Abstract no. 32347, 1998.
-
Oscherwitz T, Tulsky JP, Roger S, et al. Detention of
persistantly nonadherent patients with tuberculosis.
Journal of the American Medical Association
1997;278: 843-846.
-
Osher, Fred. Personal communication. Baltimore, MD: 1999.
-
Pablos-Mendez A, Knirsh CA, Barr RG, et al. Nonadherence in
tuberculosis treatment: predictors and consequences in New York City.
American Journal of Medicine 1997;102: 164-170.
-
Padgett D, Streuning EL, et al. Factors affecting the use of
medical, mental health, alcohol, and drug treatment services by homeless
adults. Medical Care 1990;28: 805-821.
-
Palella FJ, Delaney KM, Moorman AC. Declining morbidity and
mortality among patients with advanced human immunodeficiency virus infection.
New England Journal of Medicine 1998;338: 853-860.
47
-
Panel on Clinical Practices for Treatment of HIV Infection.
Guidelines for the use of antiretroviral agents in HIV-infected adults and
adolescents. Washington, D.C.: DHHS/Henry J Kaiser Family Foundation. Dec
1998.
-
Paris NM, East RT, Toomey KE. HIV Seroprevalence among
Atlanta's homeless. Journal of Health Care for the
Poor and Underserved 1996;7: 83-93.
-
Parker RM, et al. A Survey of the health of homeless children
in Philadelphia shelters. American Journal of
Diseases of Children 1991;145: 520-526.
-
Paterson D, Swindell S, Mohr J, et al. How much adherence is
enough? A prospective study of adherence to protease inhibitor therapy using
MEMS caps. In: Program and Abstracts of the Sixth
Conference on Retroviruses and Opportunistic Infections;
Chicago, Ill. Abstract 92.
-
Patrick DM, Strathdee SA, Archibald CP, et al. Determinants of
HIV seroconversion in injection drug users during a period of rising
prevalence in Vancouver. International Journal of STD
& AIDS 1997;8: 437-445.
-
Patton LT. The rural homeless. In: Homelessness, Health, and
Human Needs. Washington, D.C.: Institute of Med. Nat Academy Press 1988.
-
Pfeffer G, et al. Care utilization in HIV patients at the
Medical Center of Louisiana, New Orleans. In: Abstracts International
Conference on AIDS PoD 5712.
-
Pilote L, Tulsky JP, Zolopa AR, et al. Tuberculosis prophylaxis
in the homeless: a trial to improve adherence to referral. Archives of
Internal Medicine 1996;156: 161-165.
-
Price RW, Worley JM. Management of neurologic complications of
HIV-1 infection and AIDS. In: Sande MA, Volberding PA ed. The Medical
Management of AIDS. Philadelphia, PA: W.B. Saunders Co, 1995: 261.
-
Rekart, RL, et al. Knowledge, attitudes, and behavior of
street-involved people in Vancouver. In: Abstracts
International Conference on AIDS T.D.P.8.
-
Richman DD, Havlir D, et al. Nevirapine resistance mutations of
human immunodeficiency virus type 1 selected during therapy. Journal of
Virology 1994;68: 1660-1666.
-
Richter R, Michaels M. Motivators and barriers to use of
combination therapies in patients with HIV disease. In: HIV In-Site.
San Francisco, CA: CAPS Monograph Series #5, 1998.
-
Robertson MJ, Cousineau MR. Health status and access to health
services among the urban homeless. American Journal
of Public Health 1986;76: 561-563.
-
Robertson MJ, Zlotnick C, Westerfelt. Drug use disorders and
treatment contact among homeless adults in Alameda County, California.
American Journal of Public Health 1997; 87: 221-228.
-
Rockwell R, et al. Homelessness, race, and HIV testing among
IDUs in New York City. In: Abstracts International Conference on AIDS PoD5740.
-
Ropers RH, Boyer R. Perceived health status among the new urban
homeless. Social Science Medicine
1987;24:669-678.
-
Rothenberg R, Woelfel M, Stoneburner R, et al. Survival with
the acquired immunodeficiency syndrome. New England
Journal of Medicine 1987;317: 1297-1302.
48
-
Sackett DL. Patients and therapies: Getting the two together.
New England Journal of Medicine
1978;298: 278-279.
-
Saez H, Valencia E, Conover S, Susser E. Tuberculosis and HIV
among mentally ill men in a New York City shelter. American Journal of
Public Health 1996;86: 1318-1319.
-
Salit SA, Kuhn EM, et al. Hospitalization costs associated with
homelessness in New York City. New England Journal of
Medicine 1998;338: 1734-40.
-
Samet JH, Libman, et al. Compliance with Zidovudine therapy in
patients infected with human immunodeficiency virus, type 1: A cross-sectional
study in a municipal hospital clinic. American
Journal of Medicine 1992;92: 495-501.
-
Sande MA, Volberding PA, ed. The Medical Management of AIDS.
Philadelphia, PA: W.B. Saunders Co, 1995.
-
Schambelan M, Grunfeld C. Endocrinologic manifestations of HIV
infection. In: Sande MA, Volberding PA ed. The Medical Management of AIDS.
Philadelphia, PA: W.B. Saunders Co, 1995: 353-354.
-
Schechter MT, Hogg RS, et al. Higher socioeconomic status is
associated with slower progression of HIV infection independent of access to
health care. Journal of Clinical Epidemiology 1994 47: 59-67.
-
Schilling, R, Serrano Y, et al. Predictor variables of trading
sex among male drug users in Harlem. In: Abstracts
International Conference on AIDS PoC4658, pg C352.
-
Schlossstein E, St. Clair P, et al. Referral keeping in
homeless women. Journal of Community Health
1991;16: 279-285.
-
Shelton D, et al. Issues related to health care utilization and
medical adherence among prenatal HIV seropositive African-American women in
Miami: The role of the family and the extended kinship network. Family
System Medicine 1993;11: 1-14.
-
Sherer R. Adherence and antiretroviral therapy in injection
drug users. Journal of the American Medical
Association 1998;280: 567-568.
-
Siegal HA, Carlson RG, Falck R, et al. HIV infection and risk
behaviors among intravenous drug users in low seroprevalence areas in the
Midwest. American Journal of Public Health 1991;81: 1642-1644.
-
Silha S, ed. Third National HIV/AIDS Housing Conference: New
Strategies for a Changing Environment. Washington, DC: AIDS Housing of
Washington, 1999.
-
Singh N, Squier C, Sivek C, et al. Determinants of compliance
with antiretroviral therapy in patients with human immunodeficiency virus:
prospective assessment with implications for enhancing compliance.
AIDS CARE 1996;8: 260-269.
-
Sipler A, Cross J, Lane D, et al. The relationship between
literacy, race, and adherence to potent anti-retroviral therapies. In:
Program and Abstracts of the Sixth Conference on
Retroviruses and Opportunistic Infections; Chicago,
Ill. Abstract 108.
-
Smereck GA and Hockman EM. Prevalence of HIV infection and HIV
risk behaviors associated with living place: On-the-street homeless drug users
as a special target population for public health inter-
49
vention. American Journal of Drug and Alcohol Abuse
1998;12: 299-319.
-
Smith EM, et al. Alcohol, drugs, and psychiatric comorbidity
among homeless women: An epidemiologic study. Journal of Clinical
Psychology 1993;54(3): 82-87.
-
Solomon L, Frank R, Vlahov D, Astemborski J. Utilization of
health services in a cohort of intravenous drug users with known HIV-1
serostatus. American Journal of Public Health 1991;81: 1285-1290.
-
Solomon L, Stein M, Flynn C, et al. Health services use by
urban women with or at risk for HIV-1 infection: The HIV Epidemiology Research
Study (HERS). Journal of Acquired Immune Deficiency
Syndromes and Human Retrovirology 1998;17: 253-261.
-
Solomon L, Vlahov D, Astemborski J, et al. Factors associated
with initiation of Zidovudine in a cohort of injection drug users. Journal
of Drug Issues 1995;25: 225-233.
-
Song JY, Safaien M, Strathdee SA, Celentano DD. Prevalence of
homelessness among a cohort of injection drug users. Proceedings of the 22nd
Annual Meeting of the Society for General Internal Medicine, April 29-May 1,
1999.
-
Sontag D, Richardson L. Doctors withhold HIV pill regimen from
some. The New York Times, March 2, 1997: 1,35.
-
Sorville F, et al. Use of protease inhibitors among persons
with AIDS in Los Angeles County. Journal of Acquired
Immune Deficiency Syndromes and Human Retrovirology
1997;15: 179-180
-
Sowell RL, Christensen, P. HIV infection in rural communities.
Nursing Clinics of North America
1996;31: 107-123
-
Starr P. The homeless and the public household. New England
Journal of Medicine 1998;338:1761-1762.
-
Steiner JF. Provider assessments of compliance with Zidovudine.
Archives of Internal Medicine
1995;155: 335-336.
-
Stephenson J. AIDS researchers target poor adherence.
Journal of the American Medical Association, March 1999;281(12): 1069.
-
Stone VE, et al. Race, gender, drug use, and participation in
AIDS clinical trials. Journal of General
Internal Medicine 1997;12:
150-157.
-
Stone VE, Clarke J, et al. HIV/AIDS patients' perspectives on
adhering to regimens containing protease inhibitors. Journal of General
Internal Medicine 1998;13: 586-593.
-
Strathdee SA, et al. Barriers to use of free antiretroviral
therapy in injection drug users. Journal of the
American Medical Association 1998;280: 547-549.
-
Strathdee SA, Patrick DM, et al. Social determinants predict
needle-sharing behaviour among injection drug users in Vancouver, Canada.
Addiction 1997; 92: 1339-1347.
-
Susser E, Miller M, et al. Injection drug use and risk of HIV
transmission among homeless men with mental illness. American Journal of
Psychology 1996;153: 794-798.
-
Susser E, Stuening EL, Conover S. Psychiatric problems in
homeless men. Archives of General Psychiatry
1989;46: 845-850.
50
-
Susser E, Valencia E et al. Human immunodeficiency virus sexual
risk reduction in homeless men with mental illness. Archives of General
Psychiatry 1998; 55: 266-272.
-
Susser E, Valencia E, Conover S. Prevalence of HIV infection
among psychiatric patients in a New York City men's shelter. American
Journal of Public Health 1993;83: 568-570.
-
Tisdale M, et al. Rapid in vitro selection of human
immunodeficiency virus type 1 resistant to 3'-Thiacytadine inhibitors due to a
mutation in the YMDD region of Reverse Transcriptase.
Proceedings of the National Academy of Science USA
1993; 90: 5653-5656.
-
Torres RA, et al. HIV infection among homeless men in a New
York City shelter. In: Abstracts International
Conference on AIDS M.A.P.51.
-
Torres RA, Mani S, et al. Human immunodeficiency virus
infection among homeless men in a New York City shelter: Association with
mycobacterium tuberculosis infection. Archives of
Internal Medicine 1990;150: 2030-2036.
-
Torres RA, Meni S, Martin N. Homelessness among hospitalized
patients with AIDS-related complex in New York. In: Abstracts of the
International Conference on AIDS E.691.
-
Tross S, Abdul-Quader A, et al. Determinants of sexual risk
reduction in female IV drug users recruited from the street. In: Abstracts
International Conference on AIDS Th.D.P. 17.
-
Turner BJ, et al. Predictors of delayed medical care after
first HIV+ test from a national probability sample of HIV-infected persons in
care. Journal of General Internal Medicine 1998;13(supp): 121.
-
Tynes LL, Sautter FJ. et al. Risk of HIV infection in the
homeless and chronically mentally ill. Southern
Medical Journal 1993; 86: 276-281.
-
Ugarriza DN, Fallon T. Nurses' attitudes toward homeless women:
a barrier to change. Nursing Outlook
1994;42: 26-29.
-
Ungvarski PJ. Improving patient compliance with HIV treatment
regimens. Journal of the American Medical Association
1998;280: 1745.
-
Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance
and drug failure in protease inhibitor monotherapy. Journal of the American
Medical Association 1996;276: 1955-1956.
-
Vlahov D, Munoz A, Celentano DD, et al. Risk factors for HIV-1
infection among intravenous drug users (1978-1987). In: Abstracts
International Conference on AIDS T.A.P.45.
-
Wahlberg J, Fiore J, Angarano G, Uhlen M, Albert J. Apparent
selection against transmission of Zidovudine-resistant human immunodeficiency
virus type 1 variants. Journal of Infectious Disease
1994;169: 611-614.
-
Wainberg MA and Friedland G. Public health implications of
antiretroviral therapy and HIV drug resistance. Journal of the American
Medical Association 1998;279: 1977-1983.
-
Wall TL, Sorenson JL, et al. Adherence to Zidovudine (AZT)
among HIV-infected methadone patients: a pilot study of supervised therapy and
dispensing compared to usual care. Drug and Alcohol
Dependence 1995;37: 261-269.
-
Weinreb L, Goldberg R, Perloff J. Health characteristics and
medical service use patterns of sheltered homeless and low-income mothers.
Journal of General Internal Medicine 1998;13: 389-397.
51
-
Weinreb LF, Bassuk EL. Health care of homeless families: a
growing challenge for family medicine. Journal of
Family Practice 1990;31: 74-80.
-
Weissman G, et al. Women living with substance abuse and HIV
disease: Medical care issues. Journal of the American
Women's Association 1995;50: 115-120.
-
Weissman JS, Makadon HJ, Seage GR, et al. Changes in insurance
status and access to care for persons with AIDS in the Boston Health Study.
American Journal of Public Health 1994;84: 1997-2000.
-
Wenger N, Gifford A, Liu H, et al. Patient characteristics and
attitudes associated with antiretroviral (AR) adherence. In:
Program and Abstracts of the Sixth Conference on Retroviruses
and Opportunistic Infections; Chicago, IL. Abstract
98.
-
Weslowski VB, Andrulis DP, Martin V. AIDS in Rural America.
Baltimore, MD: National Public Health and Hospital Institute 1992.
-
Westmoreland T, Federal Legislation Clinic of Georgetown
University Law Center. Medicaid & HIV/AIDS Policy: A
Basic Primer, prepared for the Henry J. Kaiser
Family Foundation, July 1999; 1:170.
-
Wheeler DA, Gibert CL, et al. Weight loss as a predictor of
survival and disease progression in HIV infection. Journal of Acquired
Immune Deficiency Syndromes and Human Retrovirology 1998; 18(1): 80-85.
-
White MC, Tulsky JP, Dawson C, et al. Association between time
homeless and perceived health status among the homeless of San Francisco.
Journal of Community Health 1997; 22: 271-282.
-
Wiebel W, et al. Risk of HIV infection among homeless IV drug
users in Chicago. In: Abstracts International
Conference on AIDS M.A.P.50.
-
Wiecha JL, Dwyer JT, Dunn-Strohecker M. Nutrition and health
services needs among the homeless. Public Health Rep
1991; 106: 364-374.
-
Williams A. Antiretroviral therapy: factors associated with
adherence. Journal of the Association of Nurses in
AIDS Care 1997; 8(Supp): 18-23.
-
Williams VG, English J. The AIDS Vancouver street outreach
program. In: Abstracts International Conference on
AIDS D.620.
-
Winkleby MA, Boyce WT. Health-related risk factors of homeless
families and single adults. Journal of Community
Health 1994; 19: 7-21.
-
Wood D, et al. Homeless and housed families in Los Angeles: A
study comparing demographic, economic, and family function characteristics.
American Journal of Public Health 1990; 80: 1049-1052.
-
Wood D, Valdez R. Barriers to medical care for homeless
families compared with housed poor families. American
Journal of the Diseases of Children 1991; 145:
1109-1115.
-
Wright JD, Weber E. Homelessness and Health. New York,
NY: McGraw-Hill, 1987.
-
Zolopa AR, Hahn JA, Gorter R, et al. HIV and tuberculosis
infection in San Francisco's homeless adults: Prevalence and risk factors in a
representative sample. Journal of the American
Medical Association 1994; 272: 455-461.
52
Appendix II - CASE HISTORIES
1.
Pierre is a 32-year-old man living on the streets. He was
referred to our clinic from our mobile van
after requesting an HIV test. He spoke little English, having
come from Haiti three years previously.
Our HIV counselor spoke only English, so he was referred to me
because of my fluency in French. He
had had no medical care since his arrival in this country. When
speaking with him, he often seemed
distracted, with wandering thoughts. I thought he had psychiatric
difficulties. This belief and his lack
of a stable situation - no housing, no support from any friends
or family - made me reluctant to test.
When I asked if there were any reasons why he thought he might
have HIV, he said he had something
on his penis. On examination, he had a growth - 3 - 4 cm. in
diameter, irregular, rough, erythematous,
with purulence - on the glans of his penis. I urged him to go to
our emergency room, but
all he wanted was the HIV test. I referred him for an evaluation
of the growth, which I felt was a
cancer that had become infected. As we awaited the escort, the
patient disappeared. I thought we
would not see again.
Pierre returned to the shelter one week later. I asked if he had
gone to the hospital. He said he had
not. He was afraid because he was undocumented in this country
and did not speak English. He
asked again to be tested for HIV. I felt reassured that he had
returned exactly one week after his first
visit, knowing it was the day I was there. We had made a
connection. He was coherent, not at all
distracted, and he responded appropriately to questions of what
his reaction would be, were he to
have a positive test result. I did pre-test counseling, drew
blood and requested that he do something
for me in return. I asked him to go to the emergency room to take
care of the lesion on his penis. I
prepared the referral papers and gave them to him.
I received the HIV test results a week-and-a-half later. He did
have antibodies to HIV. I had second
thoughts about what I had done. Two weeks after the blood test,
Pierre came to the clinic and I gave
him the results. He said he thought he would be positive. We
spoke at length. He wanted to do the
complete initial work-up, which we did. To my surprise, he showed
me a bottle of antibiotics he had
obtained in the emergency room. He had kept his part of our
bargain and had gone to the hospital,
received antibiotics and been given an appointment to the urology
clinic for a biopsy. Pierre is now
with us in the clinic receiving care.
Elizabeth Lutas, M.D.
St. Vincent's Hospital & Medical Center
Department of Community Medicine
New York, NY
November 1998
2.
Samuel is a 32-year-old man who entered our therapeutic community
for alcohol abuse treatment.
He had tested positive for HIV two years previously. He had had
no illnesses related to HIV, and he
had received no care for his infection. His initial physical
examination was normal except for periph-
53
eral generalized lymphadenopathy. Blood work was remarkable for a
CD4 count of 410 and a viral
load of 130,000. An antiretroviral regimen of AZT, Epivir and
Viracept was prescribed. It was
stressed that Viracept had to be taken on a full stomach.
We saw the patient two weeks later and-among other
things-reminded him to take Viracept after
a full meal. He told us he was doing so, with the exception of
Saturday and Sunday mornings. The
shelter in which the therapeutic community was located served
three meals on weekdays, but on
weekends served only two meals a day - brunch (at noon) and
dinner (in the evening). So on Saturdays
and Sundays, Samuel took his morning Viracept on an empty
stomach.
The problem was solved when I spoke to the shelter staff and
explained the need for the morning
meal. A list of HIV-positive patients was provided for the
kitchen staff and these individuals now are
served breakfast early Saturday and Sunday mornings in addition
to the brunch and dinner meals.
Elizabeth Lutas, M.D.
St. Vincent's Hospital & Medical Center
Department of Community Medicine
New York, NY
November 1998
3.
John is a 36-year-old man who has known about his HIV infection
for five years. He had had one episode
of pneumocystis carinii pneumonia two years previously. His CD4
count had fallen below 100
one year prior to our meeting him. He had a negative PPD and was
anergic several months before.
His physician at that time had begun isoniazid and pyroxidine to
prevent active tuberculosis.
He was thus on a complicated medical regimen, receiving Crixivan
every eight hours, Zerit twice
daily, Epivir twice daily, as well as Bactrim, Zithromax,
Isoniazid, Pyridoxine, folic acid and vitamins.
The policy of the shelter in which John lived was for the shelter
to keep the patients' medications.
The patients would come to the shelter to get their medications
twice a day, once in the morning and
once in the evening. The times of the medication call varied from
day to day. John was thus having
difficulty adhering with his medical regimen, especially the
Crixivan. On occasion, John informed us,
the evening medication call was forgotten.
When we learned about this situation, I asked to meet with the
shelter director. I explained to him
our patients' needs, such as the need to take medications at
specific times, the need to take medications
more than twice a day, and so on. The shelter director agreed to
allow our patients to keep their
medications so that they could follow their medical regimen as
closely as possible.
Elizabeth Lutas, M.D.
St. Vincent's Hospital & Medical Center
Department of Community Medicine
New York, NY
November 1998
54
4.
Michael is a 49-year-old man who had worked as a nurse. He had
cared for his partner who had died
from AIDS. Michael was tested and found to be positive for the
HIV antibody. As the infection progressed,
Michael suffered from venereal warts, recurrent herpes
infections, pneumonia and CMV infection
of his gastrointestinal tract. He became so fatigued and weakened
that he was forced to leave
work. He soon became homeless and came to New York City, where he
sought shelter at our drop-in
center.
Physical examination revealed a thin man, with herpes simplex
lesions around his mouth and anus
and venereal warts on his penis. He also had peripheral
generalized lymphadenopathy. His CD4
count at this initial encounter was 148, essentially unchanged
from his previous reported CD4 count
of 150.
He was taking medications which included Norvir, Invirase,
Rescriptor, Zovirax, Bactrin and vitamins.
The Invirase was being given in the form of soft gel-caps, which
needed to be refrigerated. This
shelter staff dispensed medications to the patients. We created a
space in the refrigerator for the Invirase
gel-caps and instructed the staff that this medicine would be
kept there. This action led to general
education of the shelter staff about antiretroviral medications -
when they should be taken; how
they should be stored; etc.
Elizabeth Lutas, M.D.
St. Vincent's Hospital & Medical Center
Department of Community Medicine
New York, NY
November 1998
5.
S. A. was 21 years old when I met her in March 1997. She was
brought to our urgent care clinic by
an outreach worker who told me that S. A. only spoke Spanish and
was recently released from jail for
prostitution. She was at the time in one of the city shelters,
where our medical and social services
staff had established a satellite clinic. S. A. is a transgender
male to female, who tested HIV-positive
a year before. She was rejected by her family in Mexico and came
to the U. S. two years ago with a
boyfriend.
Shortly after arriving in the States, S. A. was alone and
depending on sex work for income. She had
multiple sexual encounters without protection, at her clients'
request. She was smoking methamphetamines
and using injectable estrogens as frequently as she could to keep
her feminine characteristics.
At the time of her first visit, she was complaining of rectal
pain and bleeding. On physical
exam, there was a large condyloma in her rectum needing surgical
removal. Our social work team
was able to place her with the Bridge Project, a special grant
program that provides housing and ancillary
services to HIV-positive patients with dual diagnosis.
Being housed and in a more stable situation -- and seeing social
and nursing staff on a regular basis --
S. A. successfully recovered from rectal surgery. She kept her
regular follow-up appointments with
55
me. Initially, her viral load was 350,000 and her CD4 count 73. I
was concerned about when to start
antiretroviral treatment. It took time for me and the clinic
staff to educate S. A. about AIDS and the
possible consequences. Fortunately, besides her rectal problem,
she had not experienced any opportunistic
infections. I prescribed oral estrogens, so that she did not have
to buy unpredictable doses of
IM estrogens. Along with the estrogens, S. A. developed the habit
of taking prophylactic medication
and vitamin supplements. She also continued smoking speed,
however, assuring me that her use was
limited and that she always remembered to take her medication,
even under the influence. She
started to receive general assistance money, but was still doing
sex work. I review safe sex practices
during each visit.
In October 1997, almost six months after her initial visit and
frequent subsequent visits, I felt comfortable
and eager to start ART. S. A. was very young, and, during that
six months, her CD4 had
dropped to 23. She started on AZT/3TC and Nelfinavir. The regimen
caused her only minimal diarrhea,
and after a month her viral load was 16,000 and her CD4 doubled.
These results were encouraging,
but after three months, her viral load was again over 300,000. S.
A. disclosed to me that she
had stopped the Nelfinavir after the first month because there
were too many pills, and that very
rarely would she take the 3TC or AZT.
I told her to not take any of the medications; she was very
relieved. She continued taking Septra and
other medications, however. I felt responsible for this failed
attempt, thinking my message did not get
through. I had interpreted the patient's agreement to treatment
as something that she wanted, not as
something she agreed to do to please me.
Her CD4 count continued to decrease. When it reached 10, I wanted
to begin therapy again. With
the assistance of the Bridge Project physician and other staff,
we amplified the message of the importance
of being on therapy. Since May 1998, her viral load has been
undetectable and her last CD4
was 240. I keep frequent visits with her. In the past few months,
S. A. has enrolled in an English
class, and she has gained 24 pounds.
There are still many obstacles, however. The Bridge Project
housing is limited to 18 months, and her
legal status in the country is questionable. S. A. may be able to
apply for asylum due to her transgenderism
and possible life-threatening situations in Mexico if she
returns, but she may be deported if
the application is not accepted. She cannot apply for SSI, and
her educational and vocational alternatives
are almost nonexistent at this moment. Many of S.A.'s
circumstances are beyond the abilities
of our clinical team, but she is receiving life-saving treatment
and her quality of life has improved
significantly under our care. She is well engaged with our clinic
and medically, she is fine.
The other day, S. A. told me that she wants to think about
herself and work for herself. I asked her if
she could say this a year ago. She answered no - a year ago she
did not care about herself. I look at
this young person, who is smiling, growing, and developing
self-esteem in spite of the many, very difficult
obstacles in her life. I can only feel the deepest respect for
her, and I realize how much this patient
is teaching me. I tell her how great it is to be her physician.
Linette Martinez, M.D.
56
Tom Waddell Clinic, Community Health Network of San Francisco
San Francisco, CA
December 1998
6.
D. W. is a 30-year-old female I first met in our urgent care
clinic in August 1997. She had been seen
three times in urgent care in 1997 for various issues, but it was
not until June 1997 that she was diagnosed
as HIV-positive as part of the REACH project, a University of
California-San Francisco study
of HIV among homeless people in San Francisco.
On July 31, 1997, D. W. came to our urgent care clinic with a dry
cough, fever and oxygen desaturation
to 91% with exertion. She was hospitalized for PCP, and I met her
just after she was discharged
from the hospital on August 18. At that time she felt fine,
stating that she had completed her full
course of Septra. She insisted that she wanted to start
antiretroviral treatment. At that time, she was
housed via the AIDS Foundation and accompanied to the clinic by
her HIV-negative boyfriend T.
R., who seemed very supportive. She admitted to crack use, but
said that both she and T. R. had
been clean and sober for two weeks. On July 22, her viral load
had been greater than 800,000 and
her CD4 count was187. We talked about her boyfriend's
seronegative status, and stressed the importance
of using condoms.
On this first visit, I did something I probably would not do now:
I wrote a prescription for Zerit,
Epivir and Viracept. We discussed the necessity of adherence and
possible side effects. For some reason,
I sensed that D. W. was committed to sticking with therapy. I
arranged a follow-up visit with me
at the HIV clinic.
The next time I heard from D. W., however, she was in the
hospital. She had gone to the emergency
room due to a rectal tear and was complaining of sweats. It
turned out that she had only received an
eight-day course of Septra for her PCP. She was thus started on a
21-day course and given Acyclovir
for probable rectal HSV. I saw her after her discharge on August
29, and she was again doing fairly
well. By September 17, D. W.'s viral load was 3,286 and her CD4
count 221, which was very good
news for both of us and proof that she was adhering to the
antiretroviral regimen. My notes from
October 15, however, state "back on meds" so I know that there
was at least one interruption. She
was found to be PPD positive in October, and she started taking
INH. By October 29, her viral load
was undetectable and her CD4 count had risen to 446.
On December 10, D.W. informed me that she was pregnant. This had
been discovered as part of the
Partner's Project, a study of HIV-positive patients and their
seronegative partners. D. W. and T. R.
had discussed the issue of having children previously, and they
wanted to have a child. I had told
them the risks involved, and I am certain that I conveyed my
opinion that it might not be a good
idea. D. W. had had ten prior pregnancies and three prior
children. She and T. R. were fairly sure
that they wanted to keep this child. After several appointment
reschedulings, D. W. went to
BAPAC, the Bay Area clinic for HIV-positive prenatal care. She
had her first appointment January
13, 1998. BAPAC followed her throughout the pregnancy, keeping
her on the same antiretroviral
regimen, Septra, and INH. On February 10, she had an undetectable
viral load and a CD4 count of
57
457. In June 1998, D. W. delivered a healthy HIV-negative baby
girl, who is now living with T. R.'s
sister in Oakland. D. W. and the baby received peripartum AZT. D.
W. also had a tubal ligation.
I did not see D. W. again until September 14, when she came to
urgent care with pharyngitis. She
was using crack again. As of September 30, she was off
antiretroviral therapy with a CD4 count of
350 and viral load of 40,000. On November 14, she came to my HIV
clinic and wanted to restart triple
therapy, which I agreed to. D. W. and T. R. are still together.
T. R. is living in a clean and sober
post-detox residential facility and D. W. is on a waiting list
for permanent supportive housing. D. W.
and T. R. visit their daughter several times a week.
Alisa Oberschelp, M.D.
Tom Waddell Clinic, Community Health Network of San Francisco
San Francisco, CA
December 1998
7.
L. T. is an HIV-positive person without a home. He is
43-years-old with a history of long-term
homelessness, and he has been HIV-positive since 1984. He is a
Vietnam veteran and carries a diagnosis
of PTSD and schizophrenia. He came to the Tom Waddell Clinic
after being banned from
other clinics for exhibiting threatening and violent behavior. L.
T. complained of chronic back pain
and had been on opioid analgesis intermittently. He had been seen
by a psychiatrist and treated with
antipsychotics and benzodiazepines. His drug of choice is
methamphetamine, which he is trying to
stop using.
We first started seeing L. T. in 1995. At that time he was coming
to our urgent care site; later he engaged
with a primary care physician who began to treat his HIV disease
and pain. He saw the psychiatrist
at the clinic, who restarted his antipsychotic medications. For
most of that time, L. T. was
homeless and on the street. He received SSI and VA benefits, but
the money always seemed to escape
him.
L. T. spent his most of his time pushing a cart, recycling. He
would search dumpsters, seeking
plumbing supplies or other things to sell. Often, we have the
perception that individuals who are
homeless do not work hard. L. T. works harder than most people
do. Many of his crises have occurred
after an injury which prevents him from working - prevents him
from collecting things, from
walking many miles a day, from pushing around 50 - 100 pounds in
his cart.
In 1997, L. T. started antiretroviral medications, taking them
for about six months. During that time
he was housed in a single residence hotel. When he became
homeless again, however, he told me
that he knew that he would not be able to take his medications as
prescribed, and he did not want to
take them for fear of resistance. For the last year, L. T. has
been homeless and not on therapy. His
CD4 count fell to 250 and his viral load was over 300,000. He is
aware that he may be in trouble
medically.
Recently, however, he has been engaged in a new project called
TLC. TLC has more community
services, and nurses and other health care workers are able to
check with patients almost on a daily
58
basis. L. T. has been more adherent with his psychiatric
medications and his behavior has been more
stable. In the last month, L. T. secured housing with the help of
TLC, and it looks that he will be
able to stay in a residential hotel with support services.
We will begin talking about highly active antiretroviral
treatment (HAART) soon. L. T. knows that
he is medically ready. Taking a long view, L. T. is doing better
now than he was two or three years
ago. He is very well engaged in practice. HAART could save L.T.'s
life, but I am able to accept the
fact that HAART may or may not be possible.
In the two years that I have been caring for L. T. regularly, the
one thing I find most characteristic is
his chaotic ups and downs. He would come to the clinic for a
month or two, work with a case manager
and get a housing plan; then he would slip into a pattern of
being on the verge of physical violence;
and then transition back into a model patient. To most clinicians
in medical practice, this scenario
can be incredibly frustrating. A lot of the chaos has to do with
substance abuse. I always ask L.
T. about drug use, and his answer is always "two or three months
ago." He can only be honest with us
to a point and then he feels that he must hide the fact that he
is using drugs.
Barry D. Zevin, M.D.,
Medical Director
Tom Waddell Clinic, Community Health Network of San Francisco
San Francisco, CA
December 1998
8.
Larry is a 52-year-old black man who was first seen in the
Homeless Health Care Center on May 17,
1988. At the time, he was sleeping on the street and in shelters.
During 1988, he had eight clinic visits,
mainly to treat multiple episodes of tracheobronchitis and to
monitor his blood pressure. His last
visit was on April 5, 1990; at that time he left the clinic
without being seen. During the next two
years, Larry visited the clinic intermittently. His use of
alcohol and crack was heavy during this time.
On August 2, 1994, he returned to the clinic with a laceration
under his right eye; he also informed
the staff that he had been HIV-positive since May. Labs were
ordered, but Larry left without having
his blood drawn. He was referred to a caseworker, but he also
left without seeing the caseworker. In
September, he finally came back to have his blood drawn; his CD4
count at the time was 480. It
wasn't until February 1995 that he returned to the clinic, and he
allowed the provider to complete a
complete physical examination and to send appropriate tests. He
also received a flu and pneumoccocal
vaccination as well. But it wasn't until September 1995 that
Larry was seen again. During that
time, clinic staff had applied for benefits for Larry and had
devoted a considerable amount of energy
attempting to locate him. He was treated for otitis externa and
then left the clinic. He wasn't seen
again until the end of the year, when Larry appeared, demanding
treatment with AZT. He was
started - after a long discussion about treatment - on AZT as
well as MVI and given a return appointment
for the following month.
He next returned to clinic at the end of May 1996. Again, the
provider spent a long time with him
discussing the need for adherence and the importance of the
medication. He left without his full ex-
59
amination, and was not seen until August 1997. He had been
receiving care at the VA, and brought
in his medications - AZT, Epivir, Phenergan, and Desipramine. The
prescriptions were filled. He
next returned in February 1998; he was not taking antiretroviral
medications. After a long hospitalization
for multiple problems including esophageal candidiasis, Larry
returned next in July 1998. He
now weighed 97 pounds and had been given the diagnosis of
advanced AIDS and wasting syndrome.
He again became lost to follow-up until the staff saw his
obituary in the newspaper on October 10,
1998 - he had died at the local county nursing home.
This was a very difficult case due to the inability to follow
this patient on a regular basis and because
of his nonadherence to any care plan. Although he had received
repeated education on HIV, medications,
safe sex, and so on, he continued to follow his own plan - which
was based on alcohol and
drug use. He had received several detoxification treatments. It
is notable that when he was the sickest,
he was sexually active with multiple partners (names unavailable
- he couldn't remember - he
didn't even mention he was married.) He did not tell his wife
about his HIV status, and we had to
test her and tell her that she was infected with HIV.
Ardyce Ridolfo, MSN, FNP, RNC
Homeless Health Care Center
Chattanooga, TN
December 1998
9.
Miguel, a 28-year-old undocumented Mexican national, first became
known to the staff at the Albuquerque
Health Care for the Homeless in 1997. He presented as a
well-developed, well-nourished
male whose only complaint was that of pain in his left shoulder,
which had been on going for three
months following a blow he had taken during a fight. Within a
week, Miguel had a positive PPD of
23mm induration and a positive HIV test. Initial recommendations
for TB treatment included INH
therapy for one year, but realistic goals were for ten months.
Attempts by HCH staff to provide incentives or motivate Miguel
with short-term housing in exchange
for his adherence to the medication proved to be successful only
for brief periods of time. At
one point, Miguel was given the opportunity to receive free room
and board at a local retreat center
in exchange for yard work. All went well for approximately three
weeks until Miguel decided to take
his friends out for a short ride using the center's vehicle
without permission. When asked what he
had thought he was doing, he responded by saying he thought he
had the trust of the center manager.
Miguel was told he had to leave, and we did not see him until one
month later.
The local men's shelter was sympathetic to Miguel's physical and
social circumstances and also tried
to motivate him with room and board for an indeterminate amount
of time in exchange for light yard
work. In time, Miguel complained that he felt confined and
eventually left.
Miguel learned only a few words in English, but nevertheless
proved to be extremely resourceful in
finding work. His desire to send money to his family in Mexico
seemed to be his strongest reason for
continuing to live in this country. Over one-and-a-half years, he
was deported to Mexico four times;
four times he made his way back. Upon each return, he would
appear at HCH physically wasted, in
need of nourishment and rest. Each time, the challenge of finding
short-term respite for Miguel was
60
renewed.
Rachel Marzec, RN
Albuquerque Health Care for the Homeless
Albuquerque, N.M.
January 1999
10.
M. A. is a 45-year-old woman with a history of HIV disease since
May 1997.She also has a history of
depression, hepatitis C, a long-standing narcotic addiction,
amenorrhea, chronic low-back pain, is
status post-laminectomy. Originally from Phoenix, Arizona, M.A.
is divorced. She had applied for
SSI, but was declined; she is now appealing. She is a sex worker
and receives general assistance. She
has two children, six and seven years old, who are in foster
care.
Shortly after she found out that she was HIV positive, M.A. came
to the clinic to establish primary
care for her HIV disease. At that time she had no specific
complaints, but was interested in methadone
maintenance treatment for her narcotic addiction. Her viral load
was about 46,000, and her
initial CD4 count was 576. I explained the significance of these
lab values and asked her how she felt
about taking medications regularly on a long-term basis. It
quickly became obvious that she was unable
to commit to therapy. She seemed distracted by a number of needs;
for example, she needed a
letter for her SSI application, and she needed another letter in
order to receive methadone maintenance.
She did not have stable housing, and she had so many other
priorities that taking medication
on a regular basis was not one of them.
When I first see patients such as M.A. who has numerous
psychosocial problems, I prefer that they
demonstrate that they are able to visit the clinic on a regular
basis before I handle a complicated prescription.
The initial visit is used to explain treatment benefits. The
patient must show up for a follow-
up appointment, demonstrating that they are really interested and
able to comply with therapy.
After I first saw M. A., she did not return to the clinic for
about six months. At this subsequent visit,
we discussed methadone detoxification, rechecked some laboratory
tests, and scheduled a follow-up
in two weeks. Her lab work showed her viral load had increased to
almost 100,000 and her T-cell
count had decreased to 186. I referred M.A. to our case manager
to help her keep her appointment.
She did not keep the scheduled appointment, but dropped in on
another occasion. She had gonorrhea
and was willing to take Septra for PCP proplylaxis, but she was
not ready to take antiretroviral
medications. M.A. reported that she has regular clients who are
aware of her serostatus, but they
prefer not to use condoms. According to her, the unprotected sex
is consensual.
Here is a patient who would clearly benefit from therapy, but
cannot make it a priority. When I saw
her most recently, however, M.A. expressed interest in HIV
treatment, feeling that if she does not
get treatment she will die, and she is not ready to die. I
prescribed Combivir and Nevirapine, hoping
to get her started without using protease inhibitors. I am
uncertain that M.A. is able to adhere, so I
am retaining the possibility of using protease inhibitors in the
future.
61
I think M.A. trusts me and in spite of her chaotic lifestyle, she
manages to come in fairly regularly.
M.A. remains overwhelmed with other problems and still uses
heroin. She wants to get into substance
abuse treatment, but she is unable to take the first step to do
so. She is marginally housed,
living in a SRO. Depression also seems to interfere with her
ability to act, so I have added Prozac to
her regimen, hoping it will make a difference. She always has a
list of things for me to do for her, and
she relies on me for things I feel she could do for herself. I
spend time and energy trying to give her
these things, but she often abuses them to get the services she
wants.
Karen Bayle, M.D.
Tom Waddell Clinic, Community Health Network of San Francisco
San Francisco, CA
February 1999
11.
I met Mr. R. in the homeless shelter around 1994. He had been a
resident of multiple homeless shelters
in the city as well as up and down the state of California for
the past four years. A non-smoker
and non-drinker, Mr. R was generally in good health until August
1990. At that time, he was residing
in the Episcopal Sanctuary Shelter, where he was treated for a
fever and cough for six weeks before
being admitted to San Francisco General Hospital. I was doing
outreach at the shelter, and found
him in his bed with a fever of 103°F. I took him to the emergency
room and stayed with him until he
was admitted.
Mr. R. was hospitalized for two days. He had an unremarkable
work-up. However, his HIV test returned
positive. Previously, he had mentioned that he had had a negative
HIV test, but it turned
out that he had end-stage AIDS. Perhaps, he was in denial.
His initial CD4 count was 8, and his viral load was 300,000. His
fever turned out to be secondary to
cryptoccocal meningitis and pneumonia. He was treated as an
inpatient, then transferred to a longterm
care facility, Laguna Honda Hospital to complete his IV
antifungal treatment and for psychosocial
evaluation. After being discharged from Laguna Honda to a SRO
hotel, he visited the clinic
three days later. He had another fever, so he was again admitted
to the hospital.
Following his transferal back to Laguna Honda, he stayed there
for six weeks. His social worker found
housing for him at Lelan's House, a long-term living facility for
advanced HIV-positive patients. Finally,
he has stable housing. After the cryptococcal infection was
stablized, I started him on antiretroviral
therapy and prophylactic medications. He is on 3TC, D4T, Crixivan
and Sustiva. His viral
load is less than 50 and he is doing very well.
Chuck Marion, M.D.
Tom Waddell Clinic, Community Health Network of San Francisco
San Francisco, CA
February 1999
62
Appendix III - GLOSSARY
ADAP AIDS Drug Assistance Program, part
of RWCA
AIDS Acquired Immune Deficiency
Syndrome
ART Antiretroviral Therapy
BPHC Bureau of Primary Health Care,
HRSA
CD4 Blood cells destroyed by HIV during
replication; a CD4 count has been used as a
surrogate marker for HIV progression but has been replaced by
viral load measurement
in recent years.
CDC Centers for Disease Control and
Prevention, HHS
CMV Cytomegalovirus, an opportunistic
infection
CPG HIV Prevention Community Planning
Group; determines priorities at the state level
for the implementation of HIV prevention activities
HIV Human Immunodeficiency Virus
HAB HIV/AIDS Bureau, HRSA
HAART Highly Active Antiretroviral
Therapy
HCHCN Health Care for the Homeless
Clinicians' Network
HHS US Department of Health and Human
Services
HRSA Health Resources and Services
Administration, HHS
IDU Injection or Intravenous drug user
MAC Mycobacterium avium complex,
an opportunistic infection
MSA Metropolitan Statistical Area
NHCHC National Health Care for the
Homeless Council
NRTI Nucleoside Reverse Transcriptase
Inhibitor, a class of antiretroviral drug
NNRTI Non-Nucleoside Reverse
Transcriptase Inhibitor, a class of antiretroviral drug
OI Opportunistic Infection
PCP Pneumocystis carinii
pneumonia, an opportunistic infection
PI Protease Inhibitor, a class of
antiretroviral drug
RWCA Ryan White CARE Act, which
provides Federal funding for HIV-related services
STD Sexually Transmitted Disease
TB Tuberculosis
63
Appendix IV
HCH CLINICIANS' NETWORK HIV/AIDS ADVISORY COMMITTEE
John Y. Song, MD, MPH, MAT, Chair
Fellow in General Internal Medicine
The Johns Hopkins University
School of Medicine, Baltimore, Maryland
Fellow in Ethics & Public Policy
Georgetown University, Washington, DC
Velinda DeForge, MS, RN, ACRN
Aid Atlanta
Atlanta, Georgia
Joan Lebow, MD
Medical Director, Ambulatory Care
Cambridge Health Alliance
Somerville, Maine
Elizabeth Lutas, MD
Department of Community Medicine
St. Vincent's Hospital & Medical Center
New York, New York
Linette Martinez, MD
Homeless Coordinator, Tom Waddell Clinic
Community Clinic Consortium
San Francisco, California
Bob Reeg, MPA
Health Policy Analyst
National Coalition for the Homeless
Washington, DC
Ardyce S. Ridolfo, MSN, FNP, RNC
Clinical Director
Homeless Health Care Center
Chattanooga, Tennessee
Rachel Rodriguez-Marzec, BSN, RN
HIV Case Manager
Albuquerque Health Care for the Homeless
Albuquerque, New Mexico
Jacqueline P. Tulsky, MD
San Francisco General Hospital, AIDS Division
University of California
San Francisco, California
Brenda J. Proffitt, MHA
Project Director
HCH Clinicians' Network
Albuquerque, New Mexico
64
Appendix V
SYMPOSIUM ON HIV/AIDS AND HOMELESSNESS
March 19-20, 1999, Washington, DC
Participants:
David Bangsberg, MD, MPH
EPI-Center Director, Hospital Epidemiologist
Assistant Professor of Medicine
San Francisco General Hospital, UCSF
San Francisco, California
Lawrence Burley
Consumer Advocate
Unity Health Care
Washington, DC
Steven Ciesielski, MD, PhD
Homeless health care provider
Hillsboro, North Carolina
Joe Cofrancesco, MD, MPH
Assistant Professor
Johns Hopkins School of Medicine
Baltimore, Maryland
Lois Eldred, PhD
Assistant Director, Epidemiology & Research
AIDS Administration
Maryland Department of Health
Baltimore, Maryland
Mangeca Fanghaenel, RN
HIV Clinical Coordinator
Somerville Hospital
Central Street Health Center
Somerville,
Barbara Garcia
Director Community Substance Abuse Svcs
San Francisco Department of Public Health
San Francisco, California
Lillian Gelberg, MD
Associate Professor of Family Medicine
UCLA School of Medicine
Los Angeles California
Janelle Goetcheus, MD
Medical Director
Unity Health Care
Washington, DC
Mr. Cristal Holloway
Chattanooga-Hamilton County
Department of Health
Chattanooga, Tennessee
Robert Johnson, MD
Division of Adolescent and
Young Adult Medicine
University of Medicine & Dentistry - NJ
Newark, New Jersey
Joan Lebow, MD
Medical Director
Cambridge Health Alliance
Somerville, Massachusetts
Mr. John Lozier, MSSW
Executive Director
National Health Care for
the Homeless Council
Nashville, Tennessee
Elizabeth Mary Lutas, MD
Department of Community Medicine
St. Vincent's Hospital & Medical Center
New York, New York
65
Miguelina MaldoNado, MSW
Director of Govt Relations and Public Policy
National Minority Aids Council
Washington, DC
Marsha Martin, DSW
Special Assistant to the Secretary
Department of Health and Human Services
Washington, DC
Linette Martinez, MD
Homeless Coordinator
Tom Waddell Clinic, San Francisco
Community Clinic Consortium
SanFrancisco,California
Martha McKinney, PhD
President
Community Health Solutions, Inc.
Richmond, Kentucky
Jeff Menzer, RN
(recorder)
Washington, DC
Heidi Nelson, MHSA
Executive Officer
Chicago Health Outreach, Inc.
Darwin Palmer, MD
Professor Emeritus
University of New Mexico
School of Medicine
Albuquerque , New Mexico
Brenda Proffitt, MHA
Project Director
HCH Clinicians' Network
Albuquerque, New Mexico
Stephen Raffanti, MD
Medical Director
Health Management Foundation and
Comprehensive Care Center
Nashville, Tennessee
Bob Reeg
Health Policy Analyst
National Coalition for the Homeless
Washington, DC
Ardyce Ridolfo, MSN, FNP, RNC
Clinical Director
Homeless Health Care Center
Chattanooga, Tennessee
Archie Saunders
Consumer Advocate
Unity Health Care
Washington, DC
Helen Schietinger
(facilitator)
Washington, DC
John Song, MD, MPH, MAT
Division of General Internal Medicine
John Hopkins University
Baltimore, Maryland
Ed Sylvester
Consumer Advocate
Unity Health Care
Washington, DC
Rosie Watson
Consumer Advocate
Unity Health Care
Washington, DC
66
Federal Attendees:
Magda L. Barini-Garcia, MD, MPH
Chief Medical Officer
HIV Education Branch
Division of Training and Technical Assistance
HIV/AIDS Bureau
Health Resouces and Services Administration
Rockville, Maryland
Kim Y. Evans, MHS
Public Health Analyst
Office of Science and Epidemiology
HIV/AIDS Bureau
Health Resouces and Services Administration
Rockville, Maryland
Jean L. Hochron, MPH
Chief, Health Care for the Homeless Program
Division of Programs for Special Populations
Bureau of Primary Health Care
Health Resources and Services Administration
Bethesda, Maryland
Lori S. Marks, BA
Health Policy Analyst
Health Care for the Homeless Program
Bureau of Primary Health Care
Health Resources and Services Administration
Bethesda, Maryland
Back to Top
|